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Cardiovascular morbidity and mortality following anthracycline therapy poses a 
significant clinical challenge. Cardiovascular magnetic resonance (CMR) is a non-
invasive imaging modality that offers unique insight into both the 
pathophysiology and evaluation of anthracycline cardiotoxicity. This thesis 
comprises a series of investigations in patients treated with anthracycline 
chemotherapy using CMR. 
In Chapter 3, the phenotype of late stage anthracycline cardiomyopathy is 
described. Surrogate CMR markers of both focal (late gadolinium enhancement; 
LGE) and diffuse (elevated native myocardial T1 mapping measurements) fibrosis 
are associated with adverse left ventricular remodelling and impaired left 
ventricular ejection fraction (LVEF). In addition a higher rate of hospitalisation for 
heart failure was identified in patients with elevated native myocardial T1 
mapping measurements. In Chapter 4, anthracycline treated patients with 
normal range LVEF are shown to have significant perturbations of CMR derived 
2D and 3D global longitudinal strain (GLS), native myocardial T1, ECV, indexed left 
ventricular mass and indexed myocardial cell volume, compared with a control 
population of similar age, sex and LVEF. It is also demonstrated that these 
parameters have good to excellent levels of inter- and intra-observer 
reproducibility. In Chapter 5, cardiotoxicity is prospectively characterised using 
multiparametric CMR, echocardiography and blood biomarkers, including 
microRNA (miRNA). It is reported that baseline CMR derived mitral annular plane 
systolic excursion (MAPSE) and baseline circulating miRNA-181-5p and miRNA-
221-3p are associated with poor recovery of LVEF 6 months after completion of 
anthracycline chemotherapy. 
In conclusion, multiparametric CMR provides unique, valuable insights into the 
pathophysiology and cardiovascular effects of anthracycline chemotherapy, 
which could potentially inform risk stratification, monitoring and treatment 





I dedicate this thesis to my family.  To my wife Jenny, my parents David and 
Shirley and my children Matilda and Annabelle, without whose enduring support, 
I would not have completed this work.  






I would like to acknowledge the support, guidance and encouragement I received 
from my supervisor, Dr Chiara Bucciarelli-Ducci, who has trained me in all aspects 
of CMR and academia, and supported me throughout this thesis. To Professor 
David Marks, who provided advice and guidance, particularly in respect of 
haematological expertise. Thanks go to Professor Constanza Emanueli and her 
team of dedicated researchers, including Kerrie Ford and Andrew Shearn who 
performed the extraction of microRNA and coordinated the analysis of the 
samples. To Anna Baritussio, Amardeep Dastidar, Estefania De Garate, Matthew 
Williams, Bostjan Berlot, Konstantina Mitrousi, and Nikesh Chavda who assisted 
with patient recruitment, study visits and data analysis. To Giovanni Biglino who 
provided advice and statistical support, and to Simon Parvin for proofreading. I 
would also like to acknowledge the hard work of the CMR radiographers: 
Christopher Lawton, Richard Johnson, Daniel Burden, Jonathan Good, Paul 
Cundick, and Lenice McAleer and echocardiographers Martin Nelson, Sarah 
Fairbairn, and Gui Rego who acquired the imaging data for the study. Finally, 
thanks go to the patients who participated in the study, without whose time and 
generosity, this project would not have been possible. 







I declare that the work in this dissertation was carried out in accordance with the 
requirements of the University's Regulations and Code of Practice for Research 
Degree Programmes and that it has not been submitted for any other academic 
award. Except where indicated by specific reference in the text, the work is the 
candidate's own work. Work done in collaboration with, or with the assistance 
of, others, is indicated as such. Any views expressed in the dissertation are those 
of the author. 
 






The following publications arose from this research:  
1. Harries I, Biglino G, Baritussio A, De Garate E, Dastidar A, Plana JC, 
Bucciarelli-Ducci C. Long term cardiovascular magnetic resonance 
phenotyping of anthracycline cardiomyopathy. Int J Cardiol. 2019 Oct 
1;292:248-252. doi: 10.1016/j.ijcard.2019.04.026. Epub 2019 Apr 10.  
Dr Iwan Harries conceived the study, collected and analysed the data, wrote and 
edited successive versions of the manuscript and figures, and reviewed the 
manuscript critically for important intellectual content. 
 
2. Harries I, Liang K, Williams M, Berlot B, Biglino G, Lancellotti P, Plana JC, 
Bucciarelli-Ducci C. Magnetic Resonance Imaging to Detect Cardiovascular 
Effects of Cancer Therapy: a Practical Guide for Cardio-Oncologists. JACC 
Cardio-Oncology. 2020 Jun. doi.org/10.1016/j.jaccao.2020.04.011 
Dr Iwan Harries helped to conceive, designed and edited successive versions of the 




The following publications were under peer review at the time of submission: 
1. Harries I Biglino G, Ford K, Nelson M, Rego G, Srivastava P, Williams M, 
Berlot B, De Garate E, Baritussio A, Liang K, Baquedano M, Chavda N,  
Lawton C, Shearn A, Otton S, Lowry L, Nightingale A, Plana JC, Marks D, 
Emmanueli C, Bucciarelli-Ducci C. Prospective Multiparametric CMR 
Characterization and microRNA Profiling of Anthracycline Cardiotoxicity: 
A Pilot Study.  
Dr Iwan Harries helped conceive and design the research, obtained ethical 
approval and funding, analysed and interpreted data, and drafted and revised the 
manuscript critically for important intellectual content 
 
2. Harries I, Berlot, ffrench-Constant N, Williams M,  Liang K, De Garate E, 
Baritussio A, Biglino G, Plana JC, Bucciarelli-Ducci C.  Cardiovascular 
Magnetic Resonance Characterization of Anthracycline Cardiotoxicity in 
Adults with Normal Left Ventricular Ejection Fraction 
Dr Iwan Harries conceived and designed the research, collected analysed and 




SIGNED:   DATE:  15th November 2020 
SIGNED:   DATE: 15th November 2020
 viii 
Other Research Output 
The following studies were published during the study period: 
1. Berlot B, Harries I, Bucciarelli-Ducci C. Connection between the heart and 
the gut.  Heart. 2019 Apr 8. pii: heartjnl-2019-314832. 
2. Milano EG, Harries IB, Bucciarelli-Ducci C. Young adult with Friedreich 
ataxia. Heart. 2019 May;105(10):797-806. 
3. Dastidar AG, Harries I, Pontecorboli G, Bruno VD, De Garate E, Moret C, 
Baritussio A, Johnson TW, McAlindon E, Bucciarelli-Ducci C. Native T1 
mapping to detect extent of acute and chronic myocardial infarction: 
comparison with late gadolinium enhancement technique.  Int J 
Cardiovasc Imaging. 2019 Mar;35(3):517-527. 
4. Rodrigues JCL, Amadu AM, Ghosh Dastidar A, Harries I, Burchell AE, 
Ratcliffe LEK, Hart EC, Hamilton MCK, Paton JFR, Nightingale AK, Manghat 
NE. Noctural dipping status and left ventricular hypertrophy: A cardiac 
magnetic resonance imaging study. J Clin Hypertens (Greenwich). 2018 
Apr;20(4):784-793 
5. Baritussio A, Ghosh Dastidar A, Frontera A, Ahmed N, De Garate E, Harries 
I, Diab I, Duncan E, Thomas G, Nisbet A, Bucciarelli-Ducci C. Diagnostic 
yield of cardiovascular magnetic resonance in young-middle aged patients 
with high-grade atrio-ventricular block. Int J Cardiol. 2017;244:335-339.  
6. Rodrigues JC, Rohan S, Ghosh Dastidar A, Harries I, Lawton CB, Ratcliffe 
LE, Burchell AE, Hart EC, Hamilton MC, Paton JF, Nightingale AK, Manghat 
NE Hypertensive heart disease versus hypertrophic cardiomyopathy: 
multi-parametric cardiovascular magnetic resonance discriminators when 






The following conference abstracts were presented during the study period: 
1. I Harries, G Biglino, B Berlot, M. Williams, V De Francesco, K Mitrousi, C 
Lawton, JC Plana, C Bucciarelli-Ducci. Myocardial fibrosis is associated 
with adverse left ventricular remodelling and heart failure 
hospitalisations in anthracycline-treated cancer survivors at 5 years 
follow-up. EuroCMR 2019. 
2. I Harries, M Curran, K Mitrousi, M Williams, B Berlot, V De Francesco, C 
Lawton, C Bucciarelli-Ducci.   Anthracycline treated cancer survivors with 
normal LVEF have significant perturbations of longitudinal strain and 
myocardial tissue composition. EuroCMR 2019. 
3. I Harries, M Williams, B Berlot, K Mitrousi, V De Francesco, U Benedetto, 
S Lyen, C Bucciarelli-Ducci. Shot through the heart. EuroCMR 2019.               
Awarded runner up prize for best case presentation. 
4. B Berlot, I Harries, G Biglino, C Bucciarelli-Ducci.  Left ventricular volumes: 
the importance of contouring the basal slice. EuroCMR 2019. 
5. I Harries, J Tan, G Biglino, AG Dastidar, A Baritussio, E De Garate, C 
Bucciarelli-Ducci. Native myocardial T1 correlates with left ventricular 
volumes and function in patients treated with anthracycline. CMR 2018. 
6. I Harries, N ffrench-Constant, G Biglino, AG Dastidar, A Baritussio, E De 
Garate, C Bucciarelli-Ducci. CMR-derived strain in adult cancer survivors 
with a normal left ventricular ejection fraction: an age and sex matched 
case-control study. CMR 2018. 
7. I Harries, AG Dastidar, A Baritussio, E De Garate, S Kestenbaum, M 
Williams, C Seyani, P Brady, J Chai, G Richards, J Bracken, V North, C 
Bucciarelli-Ducci. Gender differences in patients with late chemotherapy 
induced cardiomyopathy by CMR. EuroCMR 2017. 
8. I Harries, AG Dastidar, A Baritussio, E De Garate, T Erdei, G Pontecorboli,  
C Bucciarelli-Ducci. Native myocardial T1 and T2 mapping in healthy 
volunteers: the effect of wall thickness, gender and myocardial region at 
1.5T. EuroCMR 2017. 
 
 1 
Table of Contents 
Chapter 1 Introduction .......................................................................... 13 
Chapter 2 Literature Review .................................................................. 14 
2.1 Chemotherapy...................................................................................... 14 
2.1.1 History of anthracycline chemotherapy .......................................... 14 
2.1.2 Role of anthracycline in modern chemotherapeutic regimens ....... 15 
2.1.3 Mechanisms of action and cardiotoxicity ........................................ 15 
2.2 Definition of cardiotoxicity................................................................... 16 
2.2.1 Incidence and timing of anthracycline cardiotoxicity ...................... 16 
2.3 Cardioprotective strategies .................................................................. 20 
2.3.1 Doxorubicin analogues and administration methods ...................... 20 
2.3.2 Dexrazoxane ..................................................................................... 20 
2.3.3 Antioxidants ..................................................................................... 21 
2.3.4 Angiotensin converting enzyme inhibitors (ACEi), Angiotensin 
receptor blockers (ARB) and Beta blockers (BB) .......................................... 21 
2.3.5 Statins ............................................................................................... 23 
2.3.6 Aldosterone antagonists .................................................................. 24 
2.3.7 Other strategies ............................................................................... 24 
2.4 Detection of anthracycline cardiotoxicity ............................................ 24 
2.4.1 Biopsy ............................................................................................... 24 
2.4.2 Imaging ............................................................................................. 24 
2.4.3 Biomarkers ....................................................................................... 26 
2.5 CMR ...................................................................................................... 29 
2.5.1 CMR imaging sequences .................................................................. 29 
2.6 CMR to detect the cardiovascular effects of anthracycline ................. 43 
2.6.1 Myocardial dysfunction and heart failure........................................ 43 
 2 
2.6.2 Current international guideline recommendations on the role of 
CMR in cardio-oncology. ............................................................................... 47 
2.6.3 Problems and Safety in CMR ............................................................ 49 
2.7 Study Rationale .................................................................................... 52 
2.8 Study Objective .................................................................................... 52 
2.9 Study Aims ............................................................................................ 52 
Chapter 3 CMR Phenotyping of Long Term Anthracycline Cardiomyopathy
 53 
3.1 Introduction ......................................................................................... 53 
3.1.1 Study Objectives ............................................................................... 53 
3.2 Methods ............................................................................................... 54 
3.2.1 Study Population .............................................................................. 54 
3.2.2 Clinical Characteristics ..................................................................... 54 
3.2.3 CMR - volumes and function ............................................................ 54 
3.2.4 CMR – LGE ........................................................................................ 55 
3.2.5 CMR – Native myocardial T1 mapping ............................................. 55 
3.2.6 Statistical Analysis ............................................................................ 56 
3.3 Results .................................................................................................. 56 
3.3.1 Patient Characteristics ..................................................................... 56 
3.3.2 LGE imaging for focal myocardial fibrosis ........................................ 61 
3.3.3 Native myocardial T1 mapping techniques ..................................... 62 
3.4 Discussion ............................................................................................. 66 
3.4.1 Cardiac Morphology and Function ................................................... 66 
3.4.2 LGE Imaging - focal fibrosis .............................................................. 67 
3.4.3 Native myocardial T1 mapping – diffuse fibrosis ............................. 68 
3.4.4 Study limitations .............................................................................. 70 
 3 
3.5 Conclusion ............................................................................................ 71 
3.6 Novel Findings ...................................................................................... 71 
Chapter 4 CMR Characterisation of Anthracycline Cardiotoxicity in Adults 
with Normal Left Ventricular Ejection Fraction ............................................. 72 
4.1 Introduction ......................................................................................... 72 
4.2 Methods ............................................................................................... 73 
4.2.1 Study design and participants .......................................................... 73 
4.2.2 CMR .................................................................................................. 73 
4.2.3 Data analysis .................................................................................... 74 
4.3 Results .................................................................................................. 75 
4.3.1 Patient characteristics ...................................................................... 75 
4.3.2 Ventricular volumes and ejection fraction ...................................... 78 
4.3.3 Feature tracking strain ..................................................................... 80 
4.3.4 Tissue characterisation .................................................................... 80 
4.3.5 Left ventricular mass and myocardial cell volume........................... 80 
4.3.6 Reproducibility ................................................................................. 82 
4.5 Discussion ............................................................................................. 84 
4.5.1 Systolic function ............................................................................... 84 
4.5.2 Tissue characterisation .................................................................... 86 
4.5.3 Left ventricular mass and myocardial cell volume........................... 86 
4.5.4 Reproducibility ................................................................................. 87 
4.5.5 Study limitations .............................................................................. 87 
4.6 Conclusion ............................................................................................ 88 
4.7 Novel findings ....................................................................................... 88 
Chapter 5 Prospective Multiparametric CMR Characterisation and 
MicroRNA Profiling of Anthracycline Cardiotoxicity: A Pilot Study................. 90 
 4 
5.1 Introduction ......................................................................................... 90 
5.2 Methods ............................................................................................... 91 
5.2.1 CMR .................................................................................................. 94 
5.2.2 Echocardiography............................................................................. 94 
5.2.3 Electrocardiography ......................................................................... 95 
5.2.4 Serum Troponin I and miRNAs ......................................................... 95 
5.2.5 Data analysis .................................................................................... 96 
5.3 Results .................................................................................................. 96 
5.3.1 Patient characteristics ...................................................................... 96 
5.3.2 CMR .................................................................................................. 98 
5.3.3 Echocardiography........................................................................... 101 
5.3.4 Electrocardiography ....................................................................... 101 
5.3.5 Troponin ......................................................................................... 101 
5.3.6 Cardiovascular physiology and symptoms ..................................... 101 
5.3.7 Recovery of left ventricular ejection fraction ................................ 102 
5.4 Discussion ........................................................................................... 106 
5.4.1 CMR volumes and systolic function ............................................... 107 
5.4.2 CMR strain ...................................................................................... 108 
5.4.3 CMR T1 and T2 mapping ................................................................ 108 
5.4.4 Echocardiography........................................................................... 109 
5.4.5 MicroRNAs...................................................................................... 110 
5.4.6 Study limitations ............................................................................ 110 
5.4.7 Conclusions .................................................................................... 111 
5.5 Novel findings ..................................................................................... 111 
Chapter 6 General Discussion .............................................................. 112 
6.1 Summary of major findings ................................................................ 112 
 5 
6.2 Translational outlook ......................................................................... 114 
6.3 Limitations .......................................................................................... 115 
Chapter 7 Future directions ................................................................. 116 
Chapter 8 References .......................................................................... 117 
Chapter 9 Appendix - Prospective Study Protocol ................................. 133 
9.1 Introduction ....................................................................................... 133 
9.2 Background ........................................................................................ 134 
9.2.1 Anthracycline cardiomyopathy ...................................................... 134 
9.2.2 Current use of cardiovascular imaging to detect anthracycline 
cardiomyopathy .......................................................................................... 135 
9.2.3 Rationale for the study................................................................... 137 
9.3 Study aims .......................................................................................... 138 
9.3.1 Primary aim .................................................................................... 138 
9.3.2 Secondary aims .............................................................................. 138 
9.4 Experimental Hypothesis ................................................................... 138 
9.4.1 Hypothesis for primary aim............................................................ 138 
9.4.2 Hypothesis for secondary aim........................................................ 139 
9.5 Outcome measures ............................................................................ 139 
9.5.1 Primary outcomes .......................................................................... 139 
9.5.2 Secondary outcomes ...................................................................... 139 
9.5.3 Additional outcomes ...................................................................... 139 
9.6 Study design ....................................................................................... 139 
9.6.1 Subjects and recruitment ............................................................... 140 
9.6.2 Study schedule ............................................................................... 142 
9.6.3 Participant pathway ....................................................................... 143 
9.7 Study Procedures ............................................................................... 143 
 6 
9.7.1 Baseline data .................................................................................. 143 
9.7.2 Symptom enquiry ........................................................................... 143 
9.7.3 Physiological data ........................................................................... 143 
9.7.4 Blood sampling ............................................................................... 144 
9.7.5 MicroRNA ....................................................................................... 144 
9.7.6 CMR ................................................................................................ 144 
9.7.7 Echocardiography........................................................................... 144 
9.8 Statistics ............................................................................................. 145 
9.8.1 Justification of target sample size .................................................. 145 
9.9 Safety reporting ................................................................................. 145 
9.10 Ethical considerations ........................................................................ 146 
9.10.1 Risks and anticipated benefits ................................................... 146 
9.10.2 Informing potential participants of possible benefits and known 
risks 147 
9.10.3 Obtaining informed consent ...................................................... 147 
9.11 Research governance ......................................................................... 147 
9.11.1 Sponsor approval ....................................................................... 148 
9.11.2 Study permissions ...................................................................... 148 
9.11.3 Investigators’ responsibilities .................................................... 148 
9.11.4 Monitoring by sponsor ............................................................... 148 
9.11.5 Indemnity ................................................................................... 148 
9.12 Data protection .................................................................................. 149 




List of Figures 
Figure 2-1 Molecular structure of doxorubicin .................................................... 14 
Figure 2-2. Typical composition of a CMR imaging protocol ............................... 29 
Figure 2-3 Example anatomical CMR sequences ................................................. 31 
Figure 2-4 Abnormalities detected on anatomical sequences ............................ 32 
Figure 2-5 Still ‘cine’ images of the left ventricle ................................................. 34 
Figure 2-6 Strain overlaid bSSFP images of the left ventricle .............................. 36 
Figure 2-7 Patterns of myocardial scarring in post-contrast images using LGE .. 40 
Figure 2-8 Short axis mid ventricular native myocardial T1 maps ....................... 42 
Figure 3-1 Study population, exclusion criteria and description of subgroups. n = 
number of patients .............................................................................................. 59 
Figure 3-2 Left ventricular phenotypes in anthracycline cardiomyopathy.......... 60 
Figure 3-3 Segmental distribution of mid-myocardial LGE among patients with 
LGE........................................................................................................................ 61 
Figure-3-4 Regression analyses of absolute native myocardial T1 measurements
 .............................................................................................................................. 65 
Figure 4-1 Linear regression analysis of myocardial cell volume and doxorubicin 
dose ...................................................................................................................... 77 
Figure 4-2 Comparison of functional parameters between anthracycline treated 
patients (cases) and controls ............................................................................... 79 
Figure 4-3 Comparison of tissue parameters between anthracycline treated 
patients (cases) and controls ............................................................................... 81 
Figure 4-4 Representative case examples............................................................ 89 
Figure 5-1 Study enrolment and follow up .......................................................... 93 
Figure 5-2 Assessment of left ventricular function by tertile ............................ 103 
Figure 5-3 Dysregulation of mMiRNAs at baseline by tertile of LVEF recovery. 106 
Figure 9-1 Study schedule .................................................................................. 142 




List of Tables 
Table 2-1 Prospective adult human CMR studies of cardiotoxicity in 
chronological order .............................................................................................. 18 
Table 2-1 Prospective adult human CMR studies of cardiotoxicity in 
chronological order .............................................................................................. 45 
Table 2-2 International guideline recommendations on the use of CMR in 
oncology populations ........................................................................................... 48 
Table 2-3 Safety concerns in CMR and possible solutions ................................... 51 
Table 3-1 Clinical characteristics according to presence of LGE and native 
myocardial T1 measurements .............................................................................. 58 
Table 3-2 CMR, clinical and outcome characteristics according to presence of 
LGE and native myocardial T1 measurements..................................................... 63 
Table 4-1 Demographic data ................................................................................ 76 
Table 4-2 Interobserver reproducibility of parameters ....................................... 82 
Table 4-3 Intra-observer reproducibility of parameters ...................................... 83 
Table 5-1 Baseline data ........................................................................................ 97 
Table 5-2 Temporal changes in CMR, echocardiographic, serum and 
physiological metrics ............................................................................................ 99 
Table 5-3 Baseline data by LVEF recovery tertiles ............................................. 104 
Table 5-4 Data from completion of chemotherapy and 6 month follow up by 
LVEF recovery tertile .......................................................................................... 105 
Table 9-1 Expected adverse events not to be reported .................................... 146 
 9 
List of abbreviations  
2D  Two dimensional 
3D  Three dimensional 
ACEi  Angiotensin converting enzyme inhibitor 
AE  Adverse event 
ALL  Acute lymphoblastic leukaemia 
AML  Acute myeloid leukaemia 
ARB  Angiotensin II receptor blocker 
BB  Beta blocker 
BNP  Brain natriuretic peptide 
BMI  Body mass index 
bSSFP  Balanced Steady State Free Precession 
CMR  Cardiovascular magnetic resonance 
CT  Computerised tomography 
DNA  Deoxyribonucleic acid 
ECV   Extracellular volume 
EGE  Early gadolinium enhancement 
ESC  European society of cardiology 
FT  Feature tracking 
 10 
GCS  Global circumferential strain 
GLS  Global longitudinal strain 
GRS  Global radial strain 
HL  Hodgkin lymphoma 
ICC  Intraclass correlation coefficient 
ICI  Immune checkpoint inhibitors 
IQR  Interquartile range 
LA  Left atrium 
LAD  Left anterior descending artery 
LAVi  Left atrial volume indexed 
LCx  Left circumflex artery 
LGE  Late gadolinium enhancement 
LV  Left ventricle 
LVEDV  Left ventricular end diastolic volume 
LVEDVi  Left ventricular end diastolic volume indexed  
LVEF  Left ventricular ejection fraction 
LVESV  Left ventricular end systolic volume 
LVESVi  Left ventricular end systolic volume indexed 
LVSD  Left ventricular systolic dysfunction 
 11 
MACE  Major adverse cardiovascular event 
MAPSE  Mitral annular plane systolic excursion 
MI  Myocardial infarction 
MiRNA  Micro ribonucleic acid 
MOLLI  Modified look locker inversion recovery 
MRI  Magnetic resonance imaging 
MUGA  Multigated acquisition 
NHL  Non-Hodgkin lymphoma 
NT-pro BNP N-terminal pro brain natriuretic peptide 
NYHA  New York Heart Association 
PI  Principal Investigator 
PICC  Peripherally inserted central cannula 
PIS  Patient information sheet 
RA  Right atrium 
RCT  Randomised controlled trial 
RCA  Right coronary artery 
REC  Research Ethics Committee 
RNA  Ribonucleic acid 
RV   Right ventricle 
 12 
SAE  Serious adverse event 
SD  Standard deviation 
STIR  Short-tau inversion recovery 
TCM  Takotsubo cardiomyopathy 
T1  T1 (longitudinal) relaxation time 
T2  T2 (transverse) relaxation time 
TAPSE   Tricuspid annular plane systolic excursion 
Troponin I TnI 
Troponin T TnT 
VO2 max Maximum rate of oxygen consumption 
  
 13 
Chapter 1 Introduction  
 
Cancer is a leading cause of death affecting at least one in three people in the United Kingdom 
during their lifetime1. Advances in treatment and supportive care have led to improved survival 
for cancer patients. However, cancer therapy confers excess risk of both immediate and long 
term cardiovascular disease, and patients with established cardiovascular disease are more 
susceptible to side effects from cancer therapy. Consequently, collaboration between oncologists 
and cardiologists in the emerging field of cardio-oncology is required2. The principal aims of a 
cardio-oncologist are to eliminate cardiovascular disease as a barrier to cancer treatment, and to 
monitor and mitigate the cardiovascular side effects of cancer treatment. 
Anthracyclines are an effective treatment for many forms of cancer. However, their use is limited 
by dose dependent cardiotoxicity, which manifests clinically as left ventricular dysfunction and 
heart failure3. The mechanism of anthracycline cardiotoxicity is incompletely understood, though 
the early stages are accompanied by histological changes, which seem to predate declines in 
myocardial function4. The early histological changes are reversible if anthracycline treatment is 
discontinued5. The later stages of anthracycline cardiomyopathy are characterised by myocardial 
fibrosis6, impaired myocardial function, and are associated with a poor prognosis7, all of which 
highlights the importance of early detection of anthracycline cardiotoxicity. 
Cardiovascular magnetic resonance (CMR) is a multiparametric imaging modality that can assess 
cardiac anatomy, function, myocardial tissue properties (e.g. fibrosis), myocardial perfusion and 
blood flow in a single radiation free examination with high levels of accuracy and reproducibility, 
thus making it an important tool in the assessment of cardiovascular disease. 
This thesis describes the role of CMR in the evaluation of anthracycline cardiotoxicity. 
 
Chapter 2 Literature Review 
2.1 Chemotherapy 
The annual incidence of cancer in the United Kingdom is approximately 363,484; or one new 
diagnosis every two minutes1. However, cancer outcomes continue to improve with 50% of 
patients surviving cancer for 10 years or more1. Indeed survival trends have doubled in adults 
and tripled in children in comparison to the 1960’s1, leading to an increasing number of cancer 
survivors. Paradoxically, this has led to an increasing emphasis not only on cancer survival, but 
also on the long term effects of cancer treatment on survivors.   Early detection, surgery, 
advances in supportive care and chemotherapy have all contributed to these improvements. 
2.1.1 History of anthracycline chemotherapy 
Anthracyclines are among the most efficacious cancer therapies ever developed and were first 
isolated from Streptomyces peucetius over 50 years ago8. Indeed, anthracyclines are listed by 
the World Health Organisation among the model list of essential medicines, and despite rapid 
progress in cancer treatment and the development of novel targeted therapies, anthracyclines 
continue to play a prominent role in the treatment of several forms of cancer today. 
Doxorubicin (Figure 2-1) and daunorubicin were the first anthracyclines to be used in clinical 
practice8 and together with epirubicin and idarubicin, comprise the most common forms of 
anthracycline used in modern chemotherapeutic  regimens. 
 
Figure 2-1 Molecular structure of doxorubicin 
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2.1.2 Role of anthracycline in modern chemotherapeutic regimens 
Anthracyclines are a key component of chemotherapeutic  regimens and continue to play an 
important role in the treatment of a range of malignancies, including lymphoma, leukaemia, 
multiple myeloma, and solid tumours of the breast, lung, gastrointestinal tract, genitourinary 
system and sarcoma. For example, the majority of elderly lymphoma patients are treated with 
anthracyclines9, as are at least 50% of childhood cancer patients10.  
2.1.3 Mechanisms of action and cardiotoxicity 
Anthracyclines exert a wide variety of effects depending on the dose, method of 
administration, and target cell or cellular mechanism under investigation, though their precise 
mechanism of action, and particularly the pathophysiology of cardiotoxicity, remains unclear8. 
The following are some of the most widely accepted mechanisms thought to underpin 
cardiotoxicity.  
2.1.3.1 DNA intercalation 
Mammalian cells readily take up anthracyclines, which become localised to the nucleus and 
insert between adjacent DNA base pairs by virtue of the intercalating function of the 
chromophore moiety11. Consequently, DNA and RNA synthesis in highly replicating cells is 
inhibited, leading to therapeutic effect in malignancy. 
2.1.3.2 Reactive oxygen species/free radical formation 
Free radical formation is generally accepted to be one of the main mechanisms of 
anthracycline induced cardiotoxicity12. Excessive reactive oxygen species are generated when 
the quinone moiety of anthracyclines undergo redox reactions in the presence of oxyreductive 
enzymes such as NADH dehydrogenase8. The conversion of quinone to semiquinone also 
yields free radicals that react with oxygen, leading to the accumulation of superoxide and 
peroxide radicals13. Free cellular iron may also increase levels of reactive oxygen species with 
doxorubicin-iron complexes resulting in increased cellular stress and mitochondrial 
dysfunction13. Cardiomyocytes appear particularly susceptible to doxorubicin induced oxidant 
stress due to the increased reliance of these mitochondria dense cells on oxidative substrate 
metabolism14. Animal models have confirmed the importance of modulating reactive oxygen 
species. Overexpression of manganese dependent superoxide dismutase decreased apoptosis 
and improved left ventricular function, whereas deletion of manganese dependent 
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superoxide dismutase increased apoptosis and reduced ventricular function in mice treated 
with doxorubicin15. 
2.1.3.3 Topoisomerase II 𝜷 
DNA toposiomerases are enzymes that help to regulate DNA replication, recombination and 
transcription by introducing temporary single or double stranded DNA breaks16. Two 
isoenzymes of topoisomerase II are expressed in humans: topoisomerase II 𝛼  and 
topoisomerase IIβ. Topoisomerase II𝛼  is highly expressed in proliferating cells, whereas 
topoisomerase IIβ is highly expressed in quiescent cells, such as cardiomyocytes. Doxorubicin 
binds to topoisomerases. When bound to topoisomerase II𝛼, the cell cycle is arrested and 
apoptosis is induced17. Binding of doxorubicin to topoisomerase IIβ in cardiomyocytes also 
leads to mitochondrial dysfunction and apoptosis8. Indeed, a topoisomerase IIβ knockout 
murine model reported an absence of doxorubicin induced cardiotoxicity18. 
2.1.3.4 Other mechanisms  
Other proposed mechanisms of anthracycline induced cardiotoxicity include disruption of 
neuregulin-ErbB receptor signalling8, transcriptional changes in intracellular adenosine 
triphosphate production, downregulation of messenger RNA expression for sarcoplasmic 
reticulum, depression of glutathione peroxidase activity, and respiratory defects associated 
with mitochondrial DNA damage12. 
2.2 Definition of cardiotoxicity 
No universally accepted definition of ‘cardiotoxicity’ exists, partly because it can express an 
extremely broad variety of manifestations, depending on the agent, population, timing and 
investigative methodology employed. However, recent societal consensus statements have 
attempted to standardise the definition of cardiotoxicity relating to depressed cardiac 
function as an LVEF drop of >10 percentage points to a value below the lower limit of normal, 
typically 53% measured by echocardiography 2, 19.  
2.2.1 Incidence and timing of anthracycline cardiotoxicity 
Cardiotoxicity encompasses a broad clinical spectrum that ranges from asymptomatic but 
detectable structural or functional change or elevation of cardiac biomarkers, through to 
symptomatic heart failure. Consequently, the incidence varies according to the definition 
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employed, as well as the agent and population being studied. Using the most widely used 
definition of anthracycline cardiotoxicity (a drop in LVEF of >10 absolute percentage points  to 
a value below the limit of normal), the incidence of cardiotoxicity ranges from 1% for 
epirubicin to 48% for high dose (>700mg/m2) doxorubicin2. Median time from administration 
to diagnosis is 3.5 months with 98% of cases reported to be detectible within the first year20. 
Table 2-1 summarises prospective adult human studies of anthracycline cardiotoxicity in 
chronological order, including the definition and incidence of cardiotoxicity and main study 
findings. 
 
Table 2-1 Prospective adult human CMR studies of cardiotoxicity in chronological order 
Author and Year n Mean 
Age/Sex 







Wassmuth et al. 
2001 93 
 
22 43; 77% 
women 
First course: Doxorubicin 
67 mg/m2or Epirubicin 76 
mg/m2  
3 and 28 days 
after treatment 
initiation 
LVEF < 55% 
occurred in 27% (n 
= 6) 
Significant decrease in LVEF 67.8 ± 1.4% to 
58.9 ± 1.9%. LVEF decreased significantly at 
28 days in patients with an increase in 
relative enhancement of > 5 on day three  
Chaosuwannakit 
2010 110 
40 52; 70% 
women 
Doxorubicin 215 mg/m2 
or Daunorubicin 265 
mg/m2 or Trastuzumab 
920 mg 
4 months after 
treatment 
initiation  
Not reported Significant decrease in LVEF 58.6 ± 6.3% to 
53.9 ± 6.4%. Significant increase in aortic 
stiffness (p < .0001) 
Fallah-Rad 2011 117 42 47; 
100% 
women 





LVEF decline of 
10% to < 55% 
occurred in 24% (n 
= 10); determined 
by echo. 
Significant decrease in LVEF 66 ± 5% to 47 ± 
4% in 10 with cardiotoxicity. All of whom 
exhibited subepicardial LGE. 
Drafts et al. 2013 82 53 50; 58% 
women 
50 – 375 mg/m2 
Doxorubicin equivalent 




Of those with LVEF 
> 50% at baseline 
(n = 47), 26% (n = 
12) had LVEF <50% 
after six months 
Significant decrease in LVEF 58 ± 1% to 53 ± 
1%. Significant decrease in mean mid wall 
circumferential strain (-17.7 ± 0.4% to -15.1 ± 
0.4%; p = .0003)  
No new LGE. 
Jordan et al. 2014 65 51; 86% 
women 
55% (n = 36) received 
median 240 mg/m2 
doxorubicin equivalent, 
38% (n = 25) received a 
monoclonal antibody 
3 months after 
treatment 
initiation 
Not reported Significant decrease in LVEF 57 ± 6% to 54 ± 
7%. Significant increase in T1 weighted signal 
intensity 14.1 ± 5.1a.u. to 15.9 ± 6.8a.u.. No 
LGE. 
Lunning et al. 2015 
102 
10 59; 40% 
women 
300 mg/m2 Doxorubicin 3 months after 
treatment 
completion 
LVEF decrease by > 
10% occurred in 
50% 
Significant decrease in FT-GCS (p = .018). 
Trend to FT-GLS decrease (p = .073) 
30% exhibited one new or progressive 
segment of LGE 
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CMR= cardiovascular magnetic resonance, FT = feature tracking, GCS = global circumferential strain, GLS = global longitudinal strain, LGE = late 
gadolinium enhancement, LVEF = left ventricular ejection fraction, SENC = strain encoded imaging, RVEF = right ventricular ejection fraction





67% had epirubicin. 
100% had Trastuzumab  




No cardiotoxicity Significant decrease in LVEF (68.4 ± 6.6% to 
61.7 ± 8.7) at 6 and 12 months (62.9 ± 7.8%) 
but not at 3 months (65.4 ± 8.7%). Significant 
decrease in SENC-GLS and SEND GCS at 6 
months but not at 3 or 12 months.  







received 18 cycles of 
Trastuzumab 
6, 12 and 18 
months 
No cardiotoxicity Significant decrease in LVEF at 6 (60.4 ± 4.2% 
to 58.3 ± 5.1%) and 12 (57.9 ± 4.8%) months 
but not at 18 months. Significant decrease in 
RVEF at 6 (58.3% to 53.9%) and 12 (55%), 
which had recovered at 18 months (56.6%)   
Muehlberg et al 
2018 120 
23 59; 52% 
women 







LVEF decrease by > 
10% occurred in 
39% (n = 9)  
Significant decrease in subgroup with 
cardiotoxicity (63.5 ± 5.8% to 49.9 ± 5.0%) 
but not in those without (59.2 ± 10.3% to 
58.3 ± 7.8%). At 48hours, subgroup who 
developed cardiotoxicity had significantly 
lower native T1 times than those who did not 
develop cardiotoxicity. 
Ong et al 2018 84 41 52, 
100% 
women 
56% (n = 23) received 
anthracycline. 100% 
received Trastuzumab 




2.4% (n = 1) 
experienced 
cardiotoxicity 
Significant decrease in LVEF at 6 months 
(60.4% to 58.4%) and 12 months ( 57.9%) but 
not at 18 months (60.2%). Significant 
decrease in FT-GLS and FT-GCS at 6 and 12 
months but not at 18 months. 
2.3 Cardioprotective strategies 
Cardiomyocyte survival depends on the balance between activity in cytotoxic and 
cytoprotective pathways and an increased understanding of these pathways may inform novel 
treatments to reduce anthracycline induced cardiotoxicity14. A variety of potential 
cardioprotective strategies have been explored. These range from modified anthracycline 
preparation and administration, antioxidants and free radical scavengers, to established 
treatments of left ventricular dysfunction in other settings, such as angiotensin converting 
enzyme inhibitors (ACEi), angiotensin receptor blockers (ARB) and beta blockers. 
2.3.1 Doxorubicin analogues and administration methods 
Doxorubicin analogues, such as epirubicin and liposomal doxorubicin, are recognised to be 
relatively less cardiotoxic than doxorubicin10. A meta-analysis of 55 randomised controlled 
trials (RCTs) confirmed that the risk of clinical cardiotoxicity was significantly lower with 
epirubicin in comparison to doxorubicin (OR 0.39 95% confidence interval: 0.20-0.78), and 
liposomal in comparison to non-liposomal doxorubicin (OR 0.18 95% confidence interval: 0.08 
– 0.38), without compromising efficacy. Similar results were reported for subclinical 
cardiotoxicity. Furthermore, bolus infusion was associated with a significantly higher risk of 
clinical and subclinical cardiotoxicity in comparison to continuous infusion (OR 4.13 95% 
confidence interval 1.75-9.72) in adults10. However, this effect does not appear to extend to 
paediatric populations. A study of 102 children randomised to bolus versus continuous 
infusion of doxorubicin for acute lymphoblastic leukaemia (ALL) showed no difference in 
ventricular dimensions, ventricular function, wall thickness, ventricular mass or event free 
survival rates at a median of 8 years follow up21. Despite these findings, Smith et al. concluded 
that the evidence was not sufficiently robust to support routine clinical use of cardioprotective 
agents or liposomal doxorubicin, calling instead for an improvement in cardiac monitoring in 
oncology trials10. 
2.3.2 Dexrazoxane 
The cardioprotective effect of dexrazoxane was originally thought to be mediated by iron 
chelation but the absence of similar effects for other iron chelators, such as deferasirox 22 
argues against this hypothesis. Current thinking is that dexrazoxane confers cardioprotection 
by binding to topoisomerase II and influencing topoisomerase IIβ. Indeed this property of 
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dexrazoxane also led to concerns over a non-statistically significant increase in secondary 
malignant neoplasms reported by a meta-analysis of five paediatric RCTs (absolute incidence 
2.7% vs. 1.1%, p = .06)23. 
Meta-analysis of RCT’s indicates that administration of dexrazoxane in combination with 
doxorubicin or epirubicin to adult patients significantly reduces rates of clinical cardiotoxicity 
(OR 0.21 95% confidence interval 0.13-033) and subclinical cardiotoxicity (OR 0.33 95% 
confidence interval 0.20 – 0.55), in comparison to each agent alone10. This effect was 
replicated in a paediatric meta-analysis of five RCTs and 12 non-randomised studies that 
reported a statistically significant reduction in both clinical cardiotoxicity (RR 0.29) and 
subclinical cardiotoxicity (RR 0.43) associated with dexrazoxane use23. 
2.3.3 Antioxidants 
Due to the proposed involvement of free radical and reactive oxygen species in the 
pathophysiology of anthracycline induced cardiotoxicity, there has been considerable interest 
in the potential role of antioxidants as cardioprotective agents. Indeed, animal studies have 
reported encouraging results. For example, antioxidant treatment can cause Akt activation 
and it has been shown that intracoronary Akt1 gene delivery protected left ventricular 
function and left ventricular growth in rats treated with doxorubicin24. However, these 
findings have not been replicated in human studies.  The largest study to date randomised 54 
patients receiving doxorubicin to either N-acetylcysteine or placebo and found no difference 
in the incidence of clinical heart failure (12.5% vs. 10%, p = .77)25. 
A study of 20 children with ALL or NHL treated with anthracycline reported a significant 
difference in the percentage left ventricular fractional shortening occurring in 10 patients 
treated with coenzyme Q10, compared with those not treated with Coenzyme Q10, as well as 
a decrease in left ventricular wall thickening in the latter group, suggesting a cardioprotective 
effect for conenzyme Q1026, though these findings are yet to be replicated in larger studies. 
2.3.4 Angiotensin converting enzyme inhibitors (ACEi), Angiotensin receptor 
blockers (ARB) and Beta blockers (BB) 
Carvedilol is a non-selective 𝛽antagonist that reduces the risk of death and hospitalisation for 
cardiovascular causes in patients with left ventricular systolic dysfunction27. Consequently, its 
role in the prevention and treatment of anthracycline cardiomyopathy has been the subject 
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of several studies. In one of the first studies, 70 adult female patients were randomised to 
6.25mg carvedilol monotherapy or placebo prior to commencing doxorubicin treatment. In 
contrast to those in the placebo group, the carvedilol group showed no significant reduction 
in echo derived strain parameters one week after initiation of chemotherapy28. However, a 
recent meta-analysis of nine RCTs comprising 717 patients concluded that preventive use of 
carvedilol may be associated with a reduced incidence of LVSD, better diastolic function, and 
lower troponin I levels, though validation by larger studies over longer periods was 
recommended29. Two studies have reported similar findings for carvedilol in paediatric 
populations30, 31 and one study of adult females suggested a class effect by reporting that 
nebivolol conferred cardioprotection by maintaining LVEF in comparison to placebo at six 
months32.  
Metoprolol and candesartan combination therapy was recently evaluated in 120 patients 
receiving adjuvant anthracycline containing  regimens with or without trastuzumab for breast 
cancer by the 2x2 factorial, randomised, double blind, placebo controlled PRADA (PRevention 
of cArdiac Dysfunction during Adjuvant breast cancer therapy) trial33, which was one of the 
first RCTs to employ CMR to determine the primary endpoint of change in LVEF from baseline 
to end of chemotherapy. Interestingly, candesartan provided cardioprotection by maintaining 
LVEF (percentage point drop in candesartan group 0.8 vs. 2.6% in placebo group, p = 0.026) 
but metoprolol did not33.  
The OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol 
in patients submitted to intensive ChemOtheapy for the treatment of Malignant hEmopathies) 
evaluated prophylactic combination enalapril and carvedilol to control in 90 adult patients 
with normal LVEF34, and used a combination of echocardiography and CMR to determine the 
absolute change in LVEF from baseline. LVEF decreased significantly in the control group but 
did not change in those receiving carvedilol and enalapril, which resulted in a -3.1% difference 
by echocardiography (p = .035) and -3.4% difference (p = .09) in the 59 patients who 
underwent CMR. This also translated to a significant reduction in the composite end point of 
death or heart failure (6.7% vs. 22%, p = .036)34. Furthermore, patients with acute leukaemia 
had a greater degree of LVEF decline than patients undergoing autologous stem cell transplant 
(mean -6.4% vs. -1.0%)34.  
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The double blind, placebo controlled MANTICORE trial (Multidisciplinary Approach to Novel 
Therapies in Cardio-Oncology Research) evaluated the role of 2 - 8mg perindopril (n = 33), 2.5-
10mg bisoprolol (n = 31) or placebo (n = 30) in 94 adult female patients receiving trastuzumab 
with or without doxorubicin or epirubicin for breast cancer, using CMR derived LVEDVi and 
LVEF as the primary outcome measures35. Trastuzumab mediated increases in LVEDVi were 
similar in the bisoprolol (+8ml ± 9ml/m2), perindopril (+7 ± 14ml/m2), and placebo (+4ml ± 
11ml/m2) groups (p = .36)35. Trastuzumab mediated decline in LVEF was attenuated in the 
bisoprolol group (-1 ± 5%), relative to the perindopril (-3 ± 4%) and placebo (-5 ± 5%) groups 
(p = .001) and perindopril and bisoprolol were independent predictors of maintained LVEF on 
multivariable analysis35. Furthermore, these treatments were well tolerated with no serious 
adverse events during the study. However, the authors concluded that trastuzumab mediated 
left ventricular remodelling (the primary outcome measure) was not prevented. 
Enalapril monotherapy initiated one month after the completion of chemotherapy and 
continued for one year was evaluated in an RCT of 114 patients (56 enalapril, 58 control) with 
raised troponin I after high dose anthracycline chemotherapy36. 43% of control subjects and 
0% enalapril subjects (p < .001) experienced a > 10% decline in LVEF to < 50%, measured by 
echocardiography. A large subsequent longitudinal study (median follow up 5.2 years, IQR 2.6 
- 8.0 years) of 2625 patients by the same group reported that 98% of cardiotoxicity cases were 
detectable in the first year (median time to detection 3.5 months after chemotherapy 
completion), and that early detection and prompt initiation of heart failure therapy were 
important determinants of recovery of cardiac function20.  
2.3.5 Statins 
Statins are known to decrease atherosclerosis related morbidity and mortality, and are 
reported to have potent anti-inflammatory and antioxidant effects37. In a small study of 
patients receiving anthracycline, 20 patients were randomised to 40mg atorvastatin for six 
months and 20 to control. Echocardiography derived LVEF decreased significantly six months 
after chemotherapy in the control group (63 ± 7% to 55 ± 10%, p < .0001) but did not change 
in the atorvastatin group (61 ± 8 vs. 63 ± 9, p = .144). However, the number of patients 
experiencing an LVEF < 50% (five patients in the control group vs. one in the atorvastatin 
group) did not meet statistical significance (p = .18) 
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2.3.6 Aldosterone antagonists 
One randomised study of 25mg per day of spironolactone (n = 43) compared with placebo (n 
= 40) reported non-significant declines in LVEF in the placebo group (67.7 ± 6.3 to 53.6 ± 6.8) 
compared with the spironolactone group (67.0 ± 6.1 to 65.7 ± 7.4; p = .094), in tandem with 
preservation of diastolic function in the intervention group38 .  
2.3.7 Other strategies 
In general terms, physical activity is reported to have small to moderate beneficial effects on 
health related quality of life and cardiorespiratory fitness in women receiving treatment for 
breast cancer39. One small non-randomised study examining the effects of exercise training in 
breast cancer patients receiving anthracycline reported that decreases in VO2 max were 
attenuated by exercise training (15% vs. 4%, p = .01) and fewer patients in the exercise training 
group met functional disability criteria (7 vs. 50%, p = .01), though no between group 
differences in resting LVEF were observed40. Similar significant attenuation of NT-proBNP 
release and improvement of resting LVEF was reported following a single bout of vigorous 
intensity exercise 24 hours prior to doxorubicin in the intervention group (n = 11) in 
comparison to controls (n = 13)41. Indeed, an RCT is underway to investigate the impact of 
exercise training on cardiotoxicity and cardiac health outcomes42.  
2.4 Detection of anthracycline cardiotoxicity 
2.4.1 Biopsy 
Endomyocardial biopsy is the only method to provide direct histopathological evaluation  of 
the effects of anthracycline treatment on the myocardium and was originally described as 
early as 19784, 43. However, the inherent risks of cardiac biopsy mean that it is not feasible for 
the routine evaluation of patients receiving potentially cardiotoxic treatment. Consequently, 
the non-invasive imaging evaluation of the effects of cardiotoxic therapies have become 
established in clinical practice and will be discussed in turn. 
2.4.2 Imaging 
Cardiovascular imaging has emerged as the preferred method to evaluate and monitor cardiac 
function during anthracycline chemotherapy. A variety of imaging techniques exist; each have 
relative advantages and disadvantages. It is important to note that the data provided by each 
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method, for example LVEF, are not interchangeable44 and it is therefore recommended that 
the same modality be used for serial evaluation wherever possible2. 
2.4.2.1 Echocardiography 
Echocardiography is the cornerstone of cardiac function imaging evaluation during potentially 
cardiotoxic chemotherapy. It is widely available, relatively cheap and provides detailed 
information on chamber volumes, systolic function, haemodynamic parameters, intracardiac 
pressure and flow. The most widely used parameter for assessing left ventricular systolic 
function in cardiovascular medicine is LVEF and this has been used as a marker for 
cardiotoxicity for over 30 years45. The most widely accepted definitions of cardiotoxicity  is an 
asymptomatic drop of > 10% to a value < 53%19. However, measuring LVEF with 
echocardiography has important limitations. Obtaining sufficient image quality can be 
difficult, particularly in patients who have had left sided breast surgery, irradiation or breast 
reconstruction/prostheses. Furthermore, these methods are angle dependent, and rely on 
geometric assumptions and operator expertise46. The coefficient of variation of two 
dimensional LVEF is reported to be approximately  12%47, 48, which hampers the ability of this 
method to detect the often subtle changes that accompany cardiotoxic therapy. It is important 
to note that the threshold to detect asymptomatic cardiotoxicity is 10%2. Using 3D 
echocardiographic methods, the reproducibility and accuracy of LVEF increases48 but the 
determination of LVEF by all methods is influenced by prevailing haemodynamic conditions 
and geometric assumptions and perhaps most importantly, a reduction in LVEF may only occur 
when tissue level damage is extensive49. Consequently, increasing interest has emerged in the 
role of non-invasive markers of early myocardial damage, such as deformation or ‘strain’ 
techniques.  The role of myocardial deformation imaging is becoming established in a variety 
of clinical scenarios with a growing body of evidence supporting its use in the setting of 
cardiotoxicity from cancer therapy49. Indeed, LVEF based and myocardial deformation based 
techniques are being evaluated by an ongoing randomised controlled trial46. Myocardial 
deformation techniques also have limitations, which include interobserver, intra-observer and 
inter-vendor variability, which lead to recommendations for serial evaluation to be performed 
using the same equipment and by the same operator, where feasible2. 
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2.4.2.2 Multigated Acquisition (MUGA) 
Multigated acquisition is a non-invasive imaging technique that uses radioactive tracers to 
evaluate the cardiac blood pool using a gamma camera, which provides accurate and 
reproducible data on LVEF50. Advantages include broad availability in certain healthcare 
systems, such as the United States of America, and reproducibility2. However, limitations 
include the use of ionizing radiation, absence of haemodynamic information or data on cardiac 
anatomy, and susceptibility to a range of artefacts. 
2.4.2.3 CMR 
CMR provides accurate, reproducible data on cardiac volumes, systolic function, flow and 
tissue characteristics (oedema, scar, fibrosis, vascularity, adiposity) in a single radiation free 
examination with versatile applications in cardio-oncology, which will be discussed in detail in 
section 2.5. 
2.4.3 Biomarkers 
A range of serological cardiotoxicity biomarkers have been investigated in the context of 
cardiotoxicity. However the utility of serological biomarkers is hampered by the difficulty in 
establishing a normal reference range, different assays, determining when during treatment 
is the optimal time to sample and also what action should be taken if an abnormal result is 
detected2.   
2.4.3.1 Troponin 
Cardiac troponin is widely used in clinical practice and its release has been associated with an 
adverse prognosis in a range of cardiovascular diseases51. In general terms, a troponin rise is 
observed in approximately one third of patients receiving anthracycline treatment52, 53. New 
elevation of troponin I has been associated with a greater incidence of cardiac events 
following chemotherapy, particularly if persistently elevated at three months53, and in single 
centre studies, is reported to identify trastuzumab treated breast cancer patients who are at 
risk of cardiotoxicity and unlikely to recover baseline cardiac function despite supportive 
medical therapy54. Furthermore, the magnitude of troponin rise has been reported to 
correlate with the degree of cardiomyocyte loss in a prospective study of breast cancer 
patients55. The utility of cardiac troponin in the context of cardiotoxic chemotherapy is further 
complicated by the observation that baseline elevation of troponin can occur due to 
 27 
malignancy itself. For example, Cardinale et al. reported that 19% of Troponin I elevations 
occurred prior to anthracycline treatment54, Auner et al. reported baseline elevation of 
troponin T in 3.8% of 78 patients with haematological malignancy and Lipshulz et al. reported 
that 10% of 119 paediatric patients with haematological malignancy had baseline elevation of 
troponin T 56. More recently, high sensitivity troponin assays have become widely available 
with several studies reporting detectable temporal changes in the context of anthracycline 
treatment. A study of 43 breast cancer patients receiving anthracycline and trastuzumab 
reported that elevation of high sensitivity cardiac troponin I at three months was an 
independent predictor of cardiotoxicity at six months57. A larger study of 81 female patients 
treated with anthracyclines, taxanes and trastuzumab by the same group described that 
elevation of high sensitivity troponin I on completion of anthracycline was predictive of 
subsequent cardiotoxicity58. In one of the largest reports on the role of biomarkers in 
predicting cardiotoxicity, Zardavas et al. reported that baseline elevation of troponin I or T 
was associated with an increased risk of trastuzumab related cardiac dysfunction in 452 
patients with breast cancer59. Furthermore, Ky et al. reported that interval changes in high 
sensitivity Troponin I were associated with a greater risk of cardiotoxicity in a multicentre 
study of 78 breast cancer patients that evaluated eight different biomarkers60. Finally, Lipshulz 
et al reported that high sensitivity troponin T levels were associated with abnormally reduced 
left ventricular mass and end diastolic wall thickness four years later61 in a paediatric study of 
119 patients treated with anthracycline. 
2.4.3.2 Natriuretic peptides  
Evaluation of brain natriuretic peptide (BNP) and its inactive N-terminal amino acid fragment 
(NT-pro-BNP) has become well established in the evaluation and monitoring of heart failure 
because they are indicative of ventricular volume overload or wall stress, and provide 
important diagnostic, therapeutic and prognostic information62. Data on the utility of 
natriuretic peptides in the context of anthracycline chemotherapy are conflicting. For 
example, a prospective study of 100 breast cancer patients receiving anthracyclines, taxanes 
and trastuzumab reported a significant correlation between NT-proBNP elevation and 
mortality at one year63. Another study of 52 patients with a variety of cancer diagnoses and 
chemotherapeutic treatment  regimens reported that a persistently elevated NT-proBNP early 
after administration of chemotherapy was strongly associated with the subsequent 
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development of diastolic cardiac dysfunction64. In one of the largest studies to date, 
conducted in a paediatric population of 205 patients with haematological malignancy, Liphultz 
et al. reported that elevation of NT-proBNP was associated with adverse left ventricular 
remodelling four years later61. By contrast, several studies have reported the absence of an 
association between natriuretic peptides and cardiotoxicity 57, 58 60 and therefore, their role in 
the context of cardiotoxic chemotherapy remains to be defined. 
2.4.3.3 MicroRNA 
MicroRNAs (miRNAs) are a novel class of short non-coding RNAs that regulate elemental 
cellular processes and gene expression, and play a critical role in cardiovascular biology65. They 
are implicated in the pathogenesis of several cardiovascular diseases and, owing to their 
relative stability in plasma and ease of quantification, have evolved to become an appealing 
diagnostic and therapeutic biomarker66. Leading on from animal data67, several reports of 
dysregulation of miRNA in the setting of cardiotoxicity in human studies have emerged. In a 
pilot study of 33 children, Leger et al. reported temporal dysregulation of miRNA 29-b and 
miRNA-499 isolated from plasma following anthracycline treatment. Furthermore, the degree 
of upregulation correlated both with anthracycline dose, and the extent of cardiac injury 
evaluated by high sensitivity troponin T68. Oatmen and colleagues conducted a study of 12 
paediatric patients treated with anthracycline chemotherapy using CMR and an unbiased, 
custom microarray of 84 miRNAs extracted from serum, compared with age matched 
reference normal patients69.  They reported that the functional domain of miRNAs associated 
with myocardial differentiation and development fell over three fold on completion of 
anthracycline. Furthermore, eight miRNAs were significantly downregulated after completion 
of anthracycline in patients with the greatest declines in LVEF (> 10%, p < .05). In a study of 55 
breast cancer patients treated with anthracycline, miRNA-1 was associated with changes in 
LVEF and showed a greater area under the curve (AUC) than high sensitivity troponin I to 
discriminate between those who did and did not develop cardiotoxicity70. By contrast, a 
separate study of 58 breast cancer patients reported that despite promising preliminary 
animal data, miRNA-208a failed as a biomarker of doxorubicin induced cardiotoxicity because 
it was not detectable in any patient at any timepoint. Overall, MiRNA represent an appealing 
biomarker for cardiotoxicity, given their stability, ease of quantification, presence in multiple 
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bodily fluids and critical role in cardiovascular biology. However their precise role merits 
further evaluation71. 
2.5 CMR 
2.5.1 CMR imaging sequences  
CMR uses a variety of imaging sequences to provide comprehensive information about the 
cardiovascular system that is tailored to the clinical question posed. The CMR protocol is 
typically chosen based on the information provided by the referring physician and it is 
therefore important that all relevant background information is included, and the clinical 
question clearly formulated. Each sequence provides specific anatomical, tissue 
characteristics, functional, flow or perfusion data. Typically, a combination of sequences is 
selected to create the CMR protocol (Figure 2-2).  
 
Figure 2-2. Typical composition of a CMR imaging protocol 
CMR protocols are composed of different imaging sequences and tailored to the clinical 
question posed. Example additional imaging sequences are represented in grey. Native 
(non-contrast) and contrast enhanced sequences occur prior to and following gadolinium 
administration, respectively. CMR = cardiovascular magnetic resonance. LV = left ventricle, 
RV = right ventricle 
Guideline directed indications for CMR are discussed later in this chapter and recently 
published appropriate use criteria72 provide a useful reference to those seeking to request 
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CMR. Each CMR imaging sequence, along with its application in the setting of anthracycline 
cardiotoxicity, will be described in turn. The Society for Cardiovascular Magnetic Resonance 
(SCMR) have published comprehensive guidelines for describing CMR techniques and 
principles73, principles of CMR reporting74, CMR image interpretation and post-processing75. 
2.5.1.1 Cardiac Anatomy - dark blood (T1 and T2 weighted) imaging, white blood 
and fat suppression sequences   
CMR protocols typically begin with cross sectional axial and/or coronal images of the thorax 
and upper abdomen that provide anatomical information about not only the cardiovascular 
system but also the remainder of the thoracic and upper abdominal anatomy (Figure 2-3). 
Major incidental extracardiac findings, which are of particular relevance in cardio-oncology 
populations, were reported to occur in 12% of CMR studies in a recent meta-analysis76. These 
findings may require additional testing and can contribute to contextualising the underlying 
cardiovascular diagnosis. 
In addition to extra-cardiac findings (Figure 2-4), anatomical sequences can provide both 
direct anatomical information e.g. pericardial thickening following radiation (Figure 2-4) and 
indirect information relating to the haemodynamic consequences of underlying disease e.g. 
pleural effusions (Figure 2-4). Incidental findings, such as primary or secondary malignancy 
may also be encountered (Figure 2-4).  
Anatomical sequences help to describe tissue properties using the signal intensity in each 
sequence, for example, fluid appears bright on T2 weighted images, which can be of particular 




Figure 2-3 Example anatomical CMR sequences  
Sequential axial black blood (A-D) and coronal white blood (E-H) CMR images through the thorax and upper abdomen.
 
Figure 2-4 Abnormalities detected on anatomical sequences 
Panel A: T1 weighted black blood turbo spin echo demonstrating diffuse pericardial 
thickening (arrowed), panel B: white blood T2 weighted axial sequence demonstrating 
bilateral pleural effusions (arrowed) due to constrictive cardiomyopathy (same patient as 




2.5.1.2 Cardiac function, ventricular volumes and mass using bSSFP cine sequences  
CMR is the gold standard for the assessment of ventricular volumes and ejection fraction (EF) 
with high levels of accuracy and reproducibility, both in health and disease in the left77,44 and 
right ventricle78. Balanced steady state free precession (bSSFP) cine sequences provide high 
resolution, time resolved images that allow excellent discrimination of the endocardial and 
epicardial borders, which are subsequently contoured to provide three dimensional (3D) 
estimations of ventricular volumes, function and mass. The left ventricle is conventionally 
assessed in three long axis planes and a stack of contiguous short axis ‘slices’ from the left 
ventricular base in the atrioventricular plane, to the apex (Figure 2-5). The long axis planes are 
similar to those obtained by echocardiography; four chamber (4c), three chamber (3c) and 
two chamber (2c) (Figure 2-5). The right ventricle can also be evaluated in the same short axis 
stack (Figure 4) or alternatively with an axial stack with similarly high levels of interobserver 
and intra-observer reliability reported for each method79.
 
Figure 2-5 Still ‘cine’ images of the left ventricle 
Example long axis views (A: four chamber, B: two chamber C: three chamber) and a stack of short axis ‘slices’ from base to apex (D). 
Endocardial borders are contoured at end diastole and end systole in each of the short axis 
(or axial) slices to provide three dimensional volumes that do not rely on the geometric 
assumptions of two dimensional (2D) methods.  However, it should be noted that volume 
estimation by CMR relies on geometric assumptions and whilst the papillary muscles are part 
of the myocardium, in clinical practice they are often included as part of the blood pool and 
thus contribute to ventricular volume75. Regional wall motion can be assessed either 
subjectively or objectively (using wall thickening or myocardial strain) and is conventionally 
reported by dividing the left ventricle into 17 equally weighted segments, as recommended 
by the American Heart Association (AHA) writing group on myocardial segmentation and 
registration for cardiac imaging80.  
Measurement of left ventricular volumes, ejection fraction and mass by CMR are highly 
accurate and have been demonstrated to be more reproducible (coefficient of variability for 
LVEF in normal subjects = 2.4%)  than left ventricular volumes and mass by echocardiography 
(coefficient of variability for LVEF in normal subjects 8.6%)  or radionuclide 
ventriculography77,44. Consequently, CMR is being employed increasingly in cardio-oncology 
research trials for precise serial evaluation of cardiac structure and function33,35.
 
 
Figure 2-6 Strain overlaid bSSFP images of the left ventricle  
Diastole (Panel A-D) and systole (E-H). A and E = two chamber view, B and F = four chamber view, C and G = mid-ventricular short axis view 
D and H = composite 3D reconstruction. Red line = endocardial border, green = epicardial border and yellow = tracked myocardial features. 
bSSFP = balanced steady state free precession
The left ventricular myocardium is an architecturally complex structure that deforms in 
longitudinal (along the long axis; apex to base), circumferential (along the circular axis) and 
radial (towards the centre of the ventricle) planes. Methods to quantify myocardial 
deformation, or strain, rely on the principle of tracking distinctive features over successive 
images and several CMR sequences have been developed for this purpose. These include 
tagging, displacement encoding with simulated echoes (DENSE), phase velocity mapping 
(PVM), strain encoded imaging (SENC) and latterly, feature tracking (FT). An advantage of FT 
strain is that it can be calculated from standard cine sequences (Figure 2-6), whereas the other 
methods require dedicated sequences to be acquired. There is emerging evidence of a 
significant incremental prognostic role for CMR strain when added to LVEF and LGE techniques 
in both ischaemic and dilated cardiomyopathies81.  A systematic review of echocardiography 
derived myocardial deformation confirmed the value of these parameters for the early 
detection of myocardial changes and prediction of anthracycline cardiotoxicity49, indeed the 
utility of strain guided echocardiography monitoring of patients receiving cardiotoxic 
chemotherapy in comparison to standard care is currently being evaluated by the SUCCOUR 
randomised controlled trial46. Whilst the CMR derived strain literature is in its infancy, initial 
reports confirm detectable temporal changes in circumferential82,83 and longitudinal84 strain 
in patients receiving cardiotoxic chemotherapy, including anthracycline. Indeed, the 
sensitivity of strain in comparison to LVEF based techniques mean that it has the potential to 
play an important role in the early detection of cardiotoxicity, though large scale confirmatory 
evidence is currently lacking. In comparison to speckle tracking echocardiography, CMR based 
feature tracking shows good agreement and appears to have comparable levels of 
reproducibility85. However, it must be noted that strain has limitations. The range of vendors 
(hardware and software), acquisition techniques and post-processing algorithms mean that 
normal reference ranges are difficult to establish. Furthermore, inter- and intra-observer 
variability, as well as interstudy reproducibility continue to present barriers to widespread 
clinical use. 
2.5.1.3 Myocardial and pericardial oedema/inflammation using T2 weighted 
imaging and native T2 mapping:  
CMR is the reference standard imaging technique to detect myocardial hyperaemia and 
oedema using both T2 and T1 weighted imaging sequences86,87. Regions of oedema and 
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inflammation exhibit higher signal intensity or enhancement on these sequences. The T2 
weighted short tau inversion recovery (T2 STIR) sequence is commonly used, though T2 
mapping and early gadolinium enhancement (T1 weighted) are also employed. Some 
sequences are assessed qualitatively e.g. T2 STIR by adjudicating signal intensity in different 
myocardial segments, whereas others are assessed quantitatively e.g. by drawing ‘regions of 
interest’ that provide a T2 mapping value in milliseconds (e.g. T2 mapping). Native myocardial 
T2 mapping is reported to be the most reproducible method in the setting of oedema 
associated with myocardial infarction88 and the utility of parametric mapping methods was 
recognised by the updated Lake Louise criteria for the evaluation of non-ischaemic myocardial 
inflammation89. A small human study showed evidence of myocardial oedema in two of seven 
patients immediately after receipt of anthracycline using CMR90 and recent animal5 and 
human91 studies reported the potential utility of native myocardial T2 mapping as a 
biosignature of early anthracycline associated cardiotoxicity. 
2.5.1.4 Detection of myocardial hyperaemia/oedema - T1 weighted early 
gadolinium enhancement (EGE) imaging:   
Following the administration of a gadolinium based contrast agent, which shortens the T1 and 
T2 relaxation time of tissue where it accumulates, T1 weighted EGE sequences have 
historically been used to evaluate myocardial oedema by exploiting the enhanced 
vasodilatation and vascular permeability of acutely inflamed tissue. EGE sequences have been 
used as a marker of myocardial injury in patients with myocarditis87 and formed part of the 
original Lake Louise diagnostic criteria. In a study of 22 patients using EGE sequences, an 
increase in myocardial signal intensity three days after the administration of anthracycline 
predicted subsequent decline in LVEF at 28 days93.  
2.5.1.5 Myocardial scarring/fibrosis - Late gadolinium enhancement (LGE) 
sequences  
LGE is the cornerstone of CMR tissue characterisation and its presence predicts adverse 
outcomes in a variety of cardiomyopathies, including coronary artery disease95, non-ischaemic 
cardiomyopathy96, hypertrophic cardiomyopathy97, cardiac sarcoidosis98, myocarditis99 and 
cardiac amyloidosis100. Gadolinium preferentially accumulates in areas of interstitial 
expansion (typically scar and fibrosis) giving these areas a hyperintense (bright) appearance 
in comparison to surrounding healthy myocardium, which appears of lower signal intensity 
 39 
(darker), because of the comparative absence of contrast. The accumulation pattern of 
contrast in the myocardium mirrors the pathophysiology of the underlying disease, defining 
ischaemic patterns (subendocardial to transmural, following the ischaemic necrotic wave 
front), and non-ischaemic patterns (mid-wall, epicardial) Figure 2-7. However, anthracycline 
related cardiac dysfunction may exhibit diffuse, rather than focal fibrosis. For example, a study 
of 10 explanted hearts with advanced anthracycline cardiomyopathy (1 death and 9 following 
cardiac transplant) demonstrated interstitial fibrosis in all patients; six with multifocal fibrosis, 
three with diffuse fibrosis and one with focal fibrosis6. Consequently, diffusely fibrosed 
myocardium has uniform signal intensity and there may be an absence of normal reference 
myocardium. Thus, the most common finding in the setting of cancer therapeutics related 
cardiac dysfunction is the absence of LGE101 and less commonly  mid-myocardial102, 103, 
epicardial and right ventricular insertion point104 LGE.  Importantly, and in contrast to other 
populations, the presence of LGE has not been associated with adverse clinical outcomes in 
cardio-oncology populations. Furthermore, its relationship with adverse left ventricular 
remodelling and clinical outcomes has not been described.
 
 
Figure 2-7 Patterns of myocardial scarring in post-contrast images using LGE 
T1 weighted post contrast short axis mid ventricular images: A: ischaemic LGE (arrowed) due to transmural infarction in the right coronary 
artery territory; B: mid-myocardial LGE in dilated cardiomyopathy (arrowed) and C: subepicardial LGE (arrowed). LGE = late gadolinium 
enhancement.
 
2.5.1.6  Intracellular and interstitial myocardial fibrosis and 
oedema/inflammation - Native and post-contrast myocardial T1 mapping 
sequences. 
Novel, advanced tissue characterisation sequences such as native T1 mapping and 
extracellular volume (ECV) fraction estimation may be able to address the perceived 
shortcomings of LGE by quantitatively assessing the extracellular space (Figure 2-8). Indeed, 
these techniques have shown excellent reproducibility and robust validation against biopsy 
proven collagen volume fraction and extracellular space reported in explanted hearts105 and 
biopsied patients with dilated cardiomyopathy106. Using this technique, an increased ECV, 
used as a surrogate marker of myocardial fibrosis, was reported in a cohort of patients 
receiving anthracyclines, as compared with age and sex matched controls107. It has also been 
shown to occur independently of underlying cancer or cardiovascular comorbidities three 
years after anthracycline treatment108. Whilst these techniques hold promise to detect the 
presence of subtle, diffuse fibrosis their precise role in the identification, monitoring and 
prognosis of anthracycline cardiotoxicity is yet to be precisely defined.  
In addition to detecting late cancer therapy related fibrosis, native myocardial T1 mapping and 
ECV can be elevated due to inflammatory myocardial processes, including early after cancer 
treatment91. Therefore, native T1 mapping and ECV should not be considered only to 
represent diffuse fibrosis, but rather to represent an estimation of the extracellular volume.
 
 
Figure 2-8 Short axis mid ventricular native myocardial T1 maps 
A: normal native myocardial measurements (1010ms) and B: abnormal measurements (1136ms) in the mid-ventricular septum. Colour scale 
is evident on the left hand side.
2.6 CMR to detect the cardiovascular effects of anthracycline 
2.6.1 Myocardial dysfunction and heart failure 
Left ventricular dysfunction that manifests clinically as heart failure is the most concerning 
complication of anthracycline chemotherapy, principally because it carries a poor prognosis, 
particularly when it is detected late7. The mechanisms underpinning cardiotoxicity were 
discussed in section 2.1.3. From a clinical perspective, two types of cardiotoxicity were 
originally described19. Type I toxicity is attributable to anthracycline e.g. Doxorubicin, is dose 
dependent, may be irreversible and is associated with typical histological changes, whereas 
type II toxicity is typically attributed to agents such as monoclonal antibodies e.g. 
Trastuzumab, occurs independent of dose, is largely reversible following interruption, and is 
not associated with histological changes. Latterly, the division of cardiotoxicity into two 
distinct types appears overly simplistic with a significant degree of overlap recognised e.g. 
reversibility of anthracycline cardiotoxicity if identified early20. 
Whilst the non-invasive evaluation of LVEF has several limitations, it is the most widely 
accepted strategy for monitoring cardiac function in oncology populations. With this in mind, 
it is important to understand that different mechanisms can drive changes in LVEF, which is a 
product of end diastolic and end systolic left ventricular volumes. One study of 120 adults 
reported that among patients with declines in LVEF meeting criteria for cardiotoxicity, 19% 
were due to an isolated fall in end diastolic volume, thought principally to represent volume 
depletion111. Furthermore, declines in LVEF driven by an increase in end systolic volume can 
be caused both by extrinsic factors such as increased afterload, as well as intrinsic myocardial 
dysfunction112. These factors ought to be borne in mind when interpreting the results of CMR 
in patients receiving cancer therapy. 
In a porcine model of anthracycline toxicity, Galan-Arriola5 demonstrated that T2 relaxation 
time prolongation was the earliest CMR parameter to change. This occurred at week six (two 
weeks after the third dose of intracoronary Doxorubicin), corresponded with 
intracardiomyocyte oedema at tissue level and importantly, identified cardiotoxicity at a 
reversible stage. Other parameters such as T1 mapping, ECV and left ventricular wall motion 
only occurred at a later stage, when histological changes became irreversible. These data are 
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yet to be replicated in a human population but highlight the potential utility of T2 mapping to 
inform treatment and monitoring strategies.   
The precision of CMR in measuring dynamic changes in ventricular volumes and ventricular 
mass make it an important tool to monitor and identify early subtle cardiac changes associated 
with cancer therapy employed by a number of prospective studies (Table 2-2) 113.  
CMR is effective in the evaluation of cardiomyopathy late after anthracycline chemotherapy, 
which is particularly relevant when managing the increasing population of paediatric and adult 
cancer survivors. Indeed, CMR identified a higher prevalence (14%) of cardiomyopathy (left 
ventricular ejection fraction < 50%) in 114 asymptomatic childhood cancer survivors assessed 
27.8 years after anthracycline chemotherapy compared with 2D or 3D echocardiography113. 
In fact, 11% of the study population were misclassified as having a normal LVEF by 2D 
echocardiography in comparison to CMR, with the higher cut off of an LVEF of 60% improving 
the detection of cardiomyopathy. In another study of 62 asymptomatic childhood cancer 
survivors assessed a median of 7.8 years after anthracycline treatment, the prevalence of 
cardiomyopathy (ejection fraction < 55%) in the right and left ventricles was 81% and 79%, 
respectively115. A subsequent study by the same group using 2D echocardiography, 3D 
echocardiography and CMR reported the prevalence of cardiomyopathy (LVEF <55%) as 78% 
in 71 survivors of childhood cancer116.  
Left ventricular mass is another CMR derived marker of interest for detecting cardiotoxicity. 
An inverse association between anthracycline dose and left ventricular mass was reported in 
a study of 91 patients with cardiomyopathy a median of 88 months after chemotherapy104, 
which is in keeping with the report of Armstrong et al. who found that 48% of patients had 
left ventricular mass two standard deviations below normal. Furthermore, in the former study, 
left ventricular mass demonstrated a strong inverse association with major adverse 
cardiovascular events and a recent report55 provided additional pathophysiological insight by 
suggesting that this decrease may be due to cardiomyocyte apoptosis.
 
Table 2-2 Prospective adult human CMR studies of cardiotoxicity in chronological order 
Author and Year n Mean 
Age/Sex 







Wassmuth et al. 
2001 93 
 




mg/m2or Epirubicin 76 
mg/m2  




LVEF < 55% 
occurred in 27% 
(n = 6) 
Significant decrease in LVEF 67.8 ± 1.4% to 
58.9 ± 1.9%. LVEF decreased significantly at 
28 days in patients with an increase in 
relative enhancement of > 5 on day three  
Chaosuwannakit 
2010 110 
40 52; 70% 
women 
Doxorubicin 215 mg/m2 
or Daunorubicin 265 
mg/m2 or Trastuzumab 
920 mg 
4 months after 
treatment 
initiation  
Not reported Significant decrease in LVEF 58.6 ± 6.3% to 
53.9 ± 6.4%. Significant increase in aortic 
stiffness (p < .0001) 
Fallah-Rad 2011 117 42 47; 
100% 
women 






LVEF decline of 
10% to < 55% 
occurred in 24% 
(n = 10); 
determined by 
echo. 
Significant decrease in LVEF 66 ± 5% to 47 ± 
4% in 10 with cardiotoxicity. All of whom 
exhibited subepicardial LGE. 
Drafts et al. 2013 82 53 50; 58% 
women 
50 – 375 mg/m2 
Doxorubicin equivalent 




Of those with 
LVEF > 50% at 
baseline (n = 47), 
26% (n = 12) had 
LVEF <50% after 
six months 
Significant decrease in LVEF 58 ± 1% to 53 ± 
1%. Significant decrease in mean mid wall 
circumferential strain (-17.7 ± 0.4% to -15.1 
± 0.4%; p = .0003)  
No new LGE. 
Jordan et al. 2014 65 51; 86% 
women 
55% (n = 36) received 
median 240 mg/m2 
doxorubicin equivalent, 
38% (n = 25) received a 
monoclonal antibody 
3 months after 
treatment 
initiation 
Not reported Significant decrease in LVEF 57 ± 6% to 54 ± 
7%. Significant increase in T1 weighted 
signal intensity 14.1 ± 5.1a.u. to 15.9 ± 
6.8a.u.. No LGE. 
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CMR= cardiovascular magnetic resonance, FT = feature tracking, GCS = global circumferential strain, GLS = global longitudinal strain, LGE = late 
gadolinium enhancement, LVEF = left ventricular ejection fraction, SENC = strain encoded imaging, RVEF = right ventricular ejection fraction.
Lunning et al. 2015 
102 
10 59; 40% 
women 
300 mg/m2 Doxorubicin 3 months after 
treatment 
completion 
LVEF decrease by 
> 10% occurred in 
50% 
Significant decrease in FT-GCS (p = .018). 
Trend to FT-GLS decrease (p = .073) 
30% exhibited one new or progressive 
segment of LGE 





67% had epirubicin. 
100% had Trastuzumab  




No cardiotoxicity Significant decrease in LVEF (68.4 ± 6.6% to 
61.7 ± 8.7) at 6 and 12 months (62.9 ± 
7.8%) but not at 3 months (65.4 ± 8.7%). 
Significant decrease in SENC-GLS and SEND 
GCS at 6 months but not at 3 or 12 months.  







received 18 cycles of 
Trastuzumab 
6, 12 and 18 
months 
No cardiotoxicity Significant decrease in LVEF at 6 (60.4 ± 
4.2% to 58.3 ± 5.1%) and 12 (57.9 ± 4.8%) 
months but not at 18 months. Significant 
decrease in RVEF at 6 (58.3% to 53.9%) and 
12 (55%), which had recovered at 18 
months (56.6%)   
Muehlberg et al 
2018 120 
23 59; 52% 
women 







LVEF decrease by 
> 10% occurred in 
39% (n = 9)  
Significant decrease in subgroup with 
cardiotoxicity (63.5 ± 5.8% to 49.9 ± 5.0%) 
but not in those without (59.2 ± 10.3% to 
58.3 ± 7.8%). At 48hours, subgroup who 
developed cardiotoxicity had significantly 
lower native T1 times than those who did 
not develop cardiotoxicity. 
Ong et al 2018 84 41 52, 
100% 
women 
56% (n = 23) received 
anthracycline. 100% 
received Trastuzumab 




2.4% (n = 1) 
experienced 
cardiotoxicity 
Significant decrease in LVEF at 6 months 
(60.4% to 58.4%) and 12 months ( 57.9%) 
but not at 18 months (60.2%). Significant 
decrease in FT-GLS and FT-GCS at 6 and 12 
months but not at 18 months. 
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2.6.2 Current international guideline recommendations on the role of CMR in cardio-
oncology. 
CMR is becoming increasingly incorporated into societal cardio-oncology guidelines. The role 
identified for CMR in the most recent publications is described in detail below. In brief, CMR is 
particularly useful when LVEF is difficult to obtain by other means158 (e.g. poor echocardiographic 
window due to left sided breast surgery, lung disease or obesity), when results obtained by other 
means are suboptimal, borderline or conflicting19 and where discontinuation of chemotherapy is 
being contemplated19. Furthermore, CMR is particularly useful in the assessment of pericardial 
disease2, 19, infiltrative diseases and cardiac masses2, 19, as well as the aetiology of left ventricular 
dysfunction and presence of scarring or fibrosis2. 
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Table 2-3 International guideline recommendations on the use of CMR in oncology populations 
European Society of Cardiology (ESC) Position Paper on cancer treatments and cardiovascular toxicity2 
• ‘CMR is useful to determine the cause of left ventricular dysfunction and to clarify left and right ventricular function in 
challenging cases (i.e. borderline or contradictory results from other imaging modalities)’. 
• ‘CMR also serves to evaluate the pericardium, especially in patients with chest irradiation’.  
• ‘LGE may be useful to detect scarring or fibrosis, which may have prognostic implications in the context of impaired left 
ventricular function. 
• CMR is an excellent test for the comprehensive evaluation of cardiac masses and infiltrative conditions.  
Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: American Society of 
Echocardiography and the European Association of Cardiovascular Imaging19 
• CMR may be particularly useful in situations in which discontinuation of chemotherapy is being entertained and/or when 
there is concern regarding echocardiographic or equilibrium radionuclide angiographic calculation of LVEF.  
• If the quality of the echocardiogram is suboptimal, CMR is recommended. 
• CMR should be considered in the evaluation of primary tumours of the heart with or without compromise of the pericardium 
or when the diagnosis of constrictive pericarditis remains uncertain after a careful echocardiographic evaluation. 
• Standard precautions for CMR safety need to be followed, including consideration of electromagnetic interference. This may 
be particularly relevant in patients with breast cancer, in whom tissue expanders placed for breast reconstruction may 
represent a hazard. 
Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical 
Practice Guideline 2017158 
• Imaging modalities such as CMR or multigated acquisition (MUGA) may be considered if an echocardiogram is not available 
or technically feasible (e.g., poor image quality as a result of body habitus, chronic lung conditions, or history of mediastinal 
surgery), with preference given to CMR. 
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2.6.3 Problems and Safety in CMR 
CMR emerged as an important tool to evaluate the cardiovascular system nearly two decades 
ago but significant barriers to its widespread use in routine clinical practice persist. CMR remains 
a comparatively time consuming and complex investigation that is typically performed in 
academic centres. It requires a cooperative patient, ideally in sinus rhythm who can hold their 
breath to provide high quality images. However, the advent of novel technologies such as 
compressed sensing real time cine CMR, self gating and artificial intelligence have the potential 
to simplify and reduce image acquisition time up to twentyfold, without compromising image 
quality159. The cost and general availability of MRI scanners is an additional problem that may 
partially be addressed by collaborative use of resources and establishment of referral pathways 
between smaller and larger institutions. Furthermore, most MRI scanners installed in the last 10 
years have the capacity to undertake cardiac imaging and data indicate that use of CMR increased 
in the United States during this period160, with over 600 centres submitting claims for CMR 
services, according to 2018 billing data furnished by the Centers for Medicare and Medicaid 
Services. 
There are an increasing number of physicians (cardiologists and radiologists) training and 
certifying worldwide and CMR expertise at both clinician and technologist level is increasing. To 
increase availability of technology and expertise, the development of technologies that allow 
remote supervision161 of CMR scanners may also have an important role to play in training staff 
in geographically remote locations. Shortened, simplified protocols coupled with increasing 
automation of acquisition, processing and analysis, as well as the potential for remote 
collaboration, image analysis and interpretation will also increase the accessibility of this 
important tool to clinicians working in a variety of healthcare settings.  
Technical challenges in CMR can often be overcome. For example, CMR may be facilitated in 
claustrophobic patients with a prone position, use of an eye mask, pre-procedural sedative or 
general anaesthetic (generally paediatric populations), the accompaniment of a friend or relative 
or by using a large bore scanner. Difficulty breath holding can be overcome by reducing the 
number of slices or phases and thus the time required for acquisition, by using a respiratory 
navigator or by acquiring images during free breathing or inspiration, rather than held expiration. 
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Image quality can be improved in patients with arrhythmia by employing arrhythmia rejection 
and/or correction protocols, or by using prospective ECG gating or real time acquisition.   Table 
2-4 describes safety concerns and proposed solutions to challenges encountered in clinical CMR.
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Table 2-4 Safety concerns in CMR and possible solutions 
Safety Concern Possible solution 
MRI  
Metallic foreign bodies (non-
clinical) 
Removal; Note intra-orbital metallic foreign bodies are an absolute contraindication to MRI scanning. 
Metallic foreign bodies (clinical) Patients with MRI conditional devices that pose no hazard in specific conditions can safely undergo MRI scanning. Consult MRI safety 
of specific product or device (e.g. mrisafety.com). 
There is increasing evidence that the risks attached to previously MRI unsafe clinical devices (e.g. legacy pacemakers, defibrillators, 
tissue expanders) can be mitigated and that patients can safely undergo MRI scanning 162, 163.  Consult MRI safety of specific product 
or device (e.g. mrisafety.com). and consult individuals/centres with expertise.  
Pregnancy Often avoided during first trimester, though risk is not known 
No known risk during second or third trimester 
Gadolinium contrast  
Allergy Gadolinium panel allergy testing  
Anaphylaxis Non-contrast study  
Pregnancy  Contrast not generally administered in the 2nd or 3rd trimester unless clinical condition makes use absolutely necessary 
Breast feeding Restriction may not be necessary; pre-CMR breast milk collection and precautionary post-CMR breast milk suspension for 24h often 
recommended. 
Renal impairment Weigh benefit and risk, minimise dose of a low risk agent, avoid repeat dose for seven days  
Haemodialysis Non-contrast study; dialyse within 24h of administration if benefit felt to outweigh risk 
CMR = cardiovascular magnetic resonance, MRI=magnetic resonance imaging 
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2.7 Study Rationale 
Data on the CMR features of anthracycline cardiomyopathy are drawn from a limited number 
of small studies. Long term data on the presence and extent of LGE (a surrogate marker of focal 
fibrosis) and native T1 mapping values (a surrogate marker of diffuse fibrosis) are limited and 
conflicting. Furthermore, the relationship between these CMR parameters and cardiac 
structure and function has not been described in detail. A better understanding of these 
features may shed light on the pathophysiology and natural history of anthracycline 
cardiomyopathy and contribute to our understanding of the condition.  
Excepting  a small number of recognised clinical risk factors, predicting anthracycline 
cardiotoxicity continues to pose a significant clinical challenge.  Therefore, the identification of 
non-invasive predictors of anthracycline cardiotoxicity, either at baseline or early during 
treatment would be of particular clinical value and may ultimately facilitate targeted treatment 
and monitoring strategies. 
2.8 Study Objective 
The overarching purpose of this study is to characterise the role of CMR in the diagnosis and 
prediction of anthracycline cardiotoxicity. 
2.9 Study Aims 
1. To characterise the long term CMR features of anthracycline cardiotoxicty in patients 
with impaired LVEF. 
2. To characterise the long term CMR features of anthracycline cardiotoxicity in patients 
with normal LVEF. 
3. To prospectively characterise the immediate and short term CMR and biomarker 
features of anthracycline cardiotoxicity. 




Chapter 3  CMR Phenotyping of Long Term Anthracycline 
Cardiomyopathy 
3.1 Introduction 
Anthracycline cardiomyopathy is increasingly recognised as an important contributor to the 
morbidity and mortality of cancer survivors 164. Consequently, international societies have 
published recommendations for the non-invasive monitoring of patients receiving potentially 
cardiotoxic agents2, 19, 158. CMR is the gold standard method for measuring ventricular 
volumes and function and has the unique capability to characterise myocardial tissue. CMR 
studies have focused on the early stages of anthracycline cardiomyopathy 82, 93, 102, 110. There 
are limited longitudinal studies examining cardiovascular structure and function over an 
extended period of time 104, 165. 
The early stages of anthracycline cardiomyopathy are characterised histologically by 
myocardial oedema, inflammation and vacuolisation101, whereas in the later stages, diffuse 
myocardial fibrosis predominates 6.  Discrete foci of myocardial fibrosis can be detected by 
LGE sequences with broad diagnostic and prognostic applications in cardiovascular 
medicine166. There are limited, somewhat conflicting data on the presence, extent and 
location of focal myocardial fibrosis detected by LGE in adult patients with anthracycline 
cardiomyopathy, 82, 102, 117, 165 though it is generally reported to be an infrequent finding101. 
Furthermore, the qualitative nature of the analysis, which relies on the presence of normal 
myocardium for reference, means that the diffuse fibrosis typically associated with 
anthracycline cardiomyopathy may not be detectable. Novel quantitative techniques such as 
native myocardial T1 mapping and myocardial ECV estimation using gadolinium based 
contrast agents may be better able to estimate diffuse fibrosis, with accumulating evidence 
of abnormal values following anthracycline treatment107, 108, 167, and correlation with exercise 
capacity167 and cardiac function107 reported in paediatric and adult populations, respectively.  
3.1.1 Study Objectives 
Therefore, the objectives of this study were to describe the long term phenotype of 
anthracycline cardiomyopathy, determine the prevalence of focal (LGE) and diffuse (elevated 
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native T1 measurements) myocardial fibrosis and their association with cardiac remodelling, 
function and clinical outcomes. 
3.2 Methods  
3.2.1 Study Population 
Consecutive patients referred for clinically-indicated CMR at a tertiary referral centre (Bristol 
Heart Institute, Bristol, United Kingdom) between January 2010 and January 2017 were 
retrospectively screened for eligibility. Indications included investigation of dyspnoea, chest 
pain and to evaluate the aetiology of left ventricular dysfunction.  Inclusion criteria were: age 
> 18 years and evidence of cardiotoxicity after anthracycline chemotherapy, which was 
defined either as an LVEF of < 57% or symptoms and/or signs of congestive heart failure. 
Exclusion criteria were: abnormal LV ejection fraction prior to therapy, concomitant cardiac 
disease that could cause heart failure including ischaemic heart disease (infarct pattern on 
LGE or inducible myocardial ischaemia during pharmacological stress), hypertrophic 
cardiomyopathy, moderate-severe valvular heart disease or valve replacement, history of 
excessive alcohol consumption (> 28 standard units per week), active thyroid disease or family 
history of cardiomyopathy in a first degree relative. Formal Research Ethics Committee (REC) 
approval was not obtained. The local institutional research and innovation department 
(Bristol Royal Infirmary) approved the study as a service evaluation exercise. All patients 
provided written consent for use of anonymised data for research purposes at the time of 
CMR.  
3.2.2 Clinical Characteristics 
The following data were collected: demographics, body surface area, body mass index, 
comorbidities, medications, cancer diagnosis, cancer therapy (including date, dose and type 
of therapy), New York Heart Association (NYHA) functional class at the time of CMR, 
hospitalisations for heart failure and all cause mortality. 
3.2.3 CMR - volumes and function 
All patients underwent CMR at 1.5 Tesla (Avanto, Siemens, Erlangen, Germany).  Short axis 
steady state free precession (SSFP) whole left ventricular (LV) cines (typical scan parameters: 
8 mm slice thickness, no slice gap, temporal resolution 38.1 ms, echo time 1.07 ms, in plane 
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pixel size 1.5 x 0.8 mm) were used to determine biventricular volumes, left atrial volumes, 
LVEF and left ventricular mass, which were indexed to body surface area, according to 
previously described methods 168. All measurements were performed by experienced CMR 
readers (IH/CBD) blinded to clinical details using previously validated169 threshold detection 
software (CMR42, Circle Cardiovascular Imaging, Calgary, Canada) by manually drawing the 
epicardial and endocardial borders at end systole and end diastole, taking particular care to 
track the mitral valve plane through the cardiac cycle. 
3.2.4 CMR – LGE 
LGE imaging was used to detect focal myocardial fibrosis according to previously described 
methods168 after the administration of 0.1 mmol/kg Gadovist (Bayer, Reading, United 
Kingdom) with an inversion time progressively set to null normal myocardium. The presence, 
location and extent of LGE in each of the 16 American Heart Association (AHA) segments was 
adjudicated qualitatively by two experienced, independent CMR readers (IH/CBD) with 
consensus required in cases of discrepancy. Readers were not blinded to anthracycline 
administration history and no control patients were assessed. Patients were divided into 
groups according to the presence of focal myocardial fibrosis. 
3.2.5 CMR – Native myocardial T1 mapping 
Native myocardial T1 maps were obtained in short axis using the modified look-locker 
inversion recovery sequence (MOLLI) i.e. 35° flip angle, 100ms minimum TI, 80ms TI 
increment, 150ms time delay with 5-(3)-3 heartbeat acquisition scheme170. Post-contrast T1 
maps were acquired using the MOLLI variant 4(1)3(1)2. Regions of interest were drawn on 
motion corrected T1 maps in the mid cavity interventricular septum to determine native 
myocardial T1 measurements using Argus software (Siemens, Germany) by an experienced 
CMR reader (IH), avoiding areas exhibiting LGE. Patients were divided into those with normal 
native myocardial T1 measurements (< 1065 ms) and those with increased native myocardial 
T1 measurements (> 1065 ms), according to the locally-established normal reference range 
of 1024 ± 41 ms for a control population of 29 subjects171. Secondary analysis, treating native 
myocardial T1 as a continuous variable was undertaken to explore correlations with cardiac 















3.2.6 Statistical Analysis 
Descriptive statistics were reported for all study data, including means and standard 
deviations for continuous variables, and counts and percentages for categorical variables. 
Differences between groups were assessed with student t test and Mann-Whitney U test for 
normally and non-normally distributed variables, respectively. Univariable and multivariable 
linear regression models were built to assess the association between outcomes of interest 
and one or more predictors, including controlling for age and gender in some of the 
associations. A p value < .05 was taken to indicate statistical significance. The analysis was 
carried out in Stata (Stata v. 13, StatCorp LLC, Texas United States). 
3.3 Results  
3.3.1 Patient Characteristics 
81 patients were eligible for inclusion (62 with LVEF < 57% and 19 with symptoms and/or signs 
of heart failure) Figure 3-1. Their baseline characteristics are summarised in Table 3-1. Mean 
age was 55 ± 14 years; 68% were women. The majority of patients were treated for breast 
cancer (58%) or haematological malignancy (38%).  56 of the patients (69%) had a baseline 
LVEF > 55% on echocardiography. Baseline data was not available for 23 patients (28%), 
commonly because their treatment was administered in excess of 10 years prior to CMR. 
Baseline echo was not undertaken in two patients (2%) due to perceived low clinical risk of 
cardiomyopathy. As a component of a variety of chemotherapeutic regimens, the mean 
cumulative equivalent doxorubicin dose was 279 ± 89 mg/m2 (range 50 – 450 mg/m2). The 
anthracycline dose did not correlate significantly with ventricular volumes or systolic function; 
neither did the administration of radiotherapy (p > .05 in all cases). Median time from therapy 
to CMR was 60 months (interquartile range 17–152 months). Follow up commenced at the 
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time of referral for CMR and medical records were reviewed a median of 21 months 
(interquartile range 12–33 months) after CMR. During this period, 28% of the study 
population were hospitalised with a diagnosis of heart failure recorded in their medical 
records and 6% died. Overall LVEF was impaired (49 ± 12%), driven by a pathologically 
increased  iLVESV (47 ± 23 ml/m2) when compared with established normal reference 
ranges172. iLVEDV (87 ± 25 ml/m2) remained within established normal reference ranges, 
albeit toward the upper limit172, as did indexed left ventricular mass (iLVM) (58 ± 15 g/m2). 
The predominant left ventricular phenotypes were (Figure 3-2): normal iLVM and normal 
iLVEDV (33%; normal phenotype), normal iLVM and high iLVEDV (22%; eccentric dilatation) 
and small iLVM and normal iLVEDV (21%; myocardial atrophy).    
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Table 3-1 Clinical characteristics according to presence of LGE and native myocardial T1 measurements 
 Cohort 
(n = 81) 
LGE  
(n = 15) 
No LGE 
 (n = 66) 
p Normal T1  
(n = 23) 
Elevated T1 
(n = 13) 
p 
Age, years 55 ± 14 57 ± 12 54 ± 15 0.55 57 ± 9 49 ± 18 0.25 
Female 55 (68) 6 (33) 49 (64) 0.01 18 (78) 9 (69) 0.55 
Body mass index, kg/m2 27 ± 6 28 ± 5 28 ± 6 0.82 28 ± 6 28 ± 5 0.13 
Body surface area, m2 1.9 ± 0.2 1.97 ± 0.17 1.89 ± 0.23 0.12 1.95 ± 0.23 1.84 ± 0.21 0.12 
Comorbidities 
 Systemic hypertension 
 Diabetes 
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 Beta blocker 
 Diuretic 



















































































 DOX, mg/ m2 
 
279 ± 89 
 
310 ± 101 
 




253.6 ± 89.2 
 
281.8 ± 61.7 
 
0.34 
Radiotherapy 43 (54) 7 (47) 36 (55) 0.50 15 (65) 7 (54) 0.66 
Therapy to CMR, months 60 (17-152) 153 ± 110  96 ± 116 0.02 94 ± 126 93 ± 85 0.53 
Values are mean ± SD , n (%), or median (25th to 75th percentile). ACE = angiotensin converting enzyme; ARB = angiotensin II receptor 












Figure 3-2 Left ventricular phenotypes in anthracycline cardiomyopathy 





3.3.2 LGE imaging for focal myocardial fibrosis 
LGE was present in 19% of patients and was located exclusively in the mid-
myocardium (non-ischaemic pattern) affecting a mean of 2.6 ± 1.4 segments in 
each patient. The commonest affected myocardial segment was the basal 
inferoseptal segment; 53% of patients with LGE exhibited it here (Figure 3-3).  
 
Figure 3-3 Segmental distribution of mid-myocardial LGE among patients with 
LGE 
Segmental distribution of LGE among subjects with mid-myocardial LGE using 
the American Heart Association (AHA) 16 segment plot. E.g. 53% of patients 
with LGE had basal inferoseptal LGE. LGE = late gadolinium enhancement 
Patients with LGE were more likely to be male (67 vs. 36%, p = .01), have diabetes 
(13% vs. 2%, p = .03) and were scanned at a greater time interval after cancer 





characteristics of patients with and without LGE were identified, including 
cumulative anthracycline dose (310 ± 101 vs. 272 ± 85 mg/m2, p = .23; Table 3-1)  
Patients with LGE had significantly reduced LVEF (43 ± 11 vs. 50 ± 12%, p = .03) 
and significantly increased  iLVEDV (102 ± 34 vs. 83 ± 21 ml/m2, p = .03), iLVESV 
(61 ± 32 vs. 43 ± 20 ml/m2, p = .03) and iLVM (65 ± 14 vs. 56 ± 14 g/m2, p = .04), 
compared with those without (Table 3-2). No significant differences in right 
ventricular volumes or systolic function, MAPSE or LAVi were observed. 
Hospitalisations with heart failure were similar between groups. Two patients 
(13%) with LGE died during follow up in comparison to three (5%) patients 
without (Table 3-2).  
Multivariable regression analysis adjusting for age, sex, and diabetic status 
showed that the presence of LGE had a significant positive association with 
iLVEDV (p = .03, CI 2.15-31.0), and iLVESV (p = .03, CI 1.29-28.2) but not with LVEF 
(p = .17, CI 11.7-2.08) or other parameters. 
3.3.3 Native myocardial T1 mapping techniques  
Native myocardial T1 mapping sequences were available for analysis in a 
subgroup of 36 patients. 23 patients (64%) had normal native myocardial T1 
measurements (1023 ± 28 ms), and 13 (36%) had increased native myocardial T1 
measurements (1092 ± 20 ms) using the mean native myocardial T1 + 1 SD (1024 
+ 41 ms = 1065 ms) of a locally derived healthy control population as a cut point 





Table 3-2 CMR, clinical and outcome characteristics according to presence of LGE and native myocardial T1 measurements 
 Cohort 
(n = 81) 
Patients with 
LGE  (n = 15) 
Patients 
without LGE (n 
= 66) 
p Patients with 
normal T1 
(n = 23) 
Patients with 
elevated T1 
(n = 13) 
p 
LV end diastolic volume index, ml/ m2 
LV end systolic volume index, ml/m2  
LV stroke volume index, ml/m2 
LV ejection fraction, % 
LV mass index, g/m2 
MAPSE, mm 
Left atrial volume index, ml/m2 
Native myocardial T1 (ms) 
Pre-contrast blood T1 (ms) 
Post-contrast myocardial T1 (ms) 
Post-contrast blood T1 (ms) 
Haematocrit (%) 
ECV (%) 
87 ± 25 
47 ± 23 
40 ± 9 
49 ± 12.0 
58 ± 15 
12 ± 3 




102 ± 34 
61 ± 32 
41 ± 8 
43 ± 11 
65 ± 14 
11 ± 2 
59 ± 24 
83 ± 21 
43 ± 20 
40 ± 9 
50 ± 12 
56 ± 14 
12 ± 3 








74 ± 19 
35 ± 15 
39 ± 8 
55 ± 9 
50 ± 12 
13 ± 3 
46 ± 14 
1023 ± 20 
1646 ±76 
505 ± 33 
354 ± 45 
37.5 ± 7.1 
28.5 ± 4.1 
97 ± 22 
56 ± 22 
41 ± 9 
44 ± 13 
63 ± 17 
12 ± 3 
56 ± 20 
1092 ± 20 
1698 ± 87 
494 ± 50 
345 ± 54 
34.7 ± 7.9 














RV end diastolic volume index, ml/ m2 
RV end systolic volume index ml/m2  
RV ejection fraction, % 
TAPSE, mm 
68 ± 16 
31 ± 11 
55 ± 9 
20 ± 5 
69 ± 17 
33 ± 14 
54 ± 9 
21 ± 4 
68 ± 16 
31 ± 10 
55 ± 9 





66 ± 12 
29 ± 8 
57 ± 7 
22 ± 5 
73 ± 15 
35 ± 13 
51 ± 11 





























































Values are mean and standard deviation (±), n (%), or median (25th to 75th percentile) 
ECV = extracellular volume fraction, CMR = Cardiovascular magnetic resonance; LGE = late gadolinium enhancement; LV = left ventricle; MAPSE = mitral annular 





Patients with increased native myocardial T1 measurements had significantly 
reduced LVEF (44 ± 13 vs. 55 ± 9%, p = .01) and significantly increased iLVEDV (97 
± 22 vs. 74 ± 19 ml/m2, p = .002) and iLVESV (56 ± 22 vs. 35 ± 15ml/m2, p = .005), 
compared with those with normal measurements (Table 3-2), differences that 
persisted in regression analysis controlling for age and sex ( LVEF [p = .003, CI -
20.4–-4.7], iLVEDV [p = .004, CI 8.8–40.9], iLVESV [p = .001, CI 9.9–37.6]. 
Regression analysis controlling for age and sex also revealed that LAVi was 
significantly increased in patients with increased native myocardial T1 
measurements (p = .02, CI 2.3–24.3). Furthermore, hospitalisations for heart 
failure were higher (38% vs. 9%, p = .03) in patients with increased native 
myocardial T1 measurements. The only death occurred in the group with normal 
native myocardial T1 measurements.  Among patients with increased native 
myocardial T1 measurements, 1 (8%) also had evidence of focal fibrosis by LGE.  
Secondary analysis treating native myocardial T1 as a continuous variable 
demonstrated significant positive correlations with iLVEDV (p < .001, CI 0.15-0.48, 
R2 0.33), iLVESV (p < .001, CI 0.15-0.44, R2 0.36), LAVi (p = .04, CI 0.01 - 0.28, 
R20.12) and LV mass indexed (p = .01, CI 0.04-0.27, 0.18); and significant negative 
correlations with LVEF (p < .001, CI -0.24- -0.08, R2 0.35) and MAPSE (p = .02, CI -
0.05 - -0.004, R2 0.14) (Figure-3-4 Panel A-F). In 31 patients with post-contrast 
mapping sequences available for analysis, ECV correlated significantly with 
iLVEDV (p = .003, CI 111-476, R2 0.27) and iLVESV (p = .02, CI 42-378, R2 0.18) but 







Figure-3-4 Regression analyses of absolute native myocardial T1 measurements  
Regression analyses demonstrates significant negative correlations with systolic function (panel A LVEF, panel E MAPSE), and significant positive 
correlations with volumes and mass (panel B LVEDVi, panel C LVESVi, panel D LVMi, and panel LAVi).

























































































































3.4 Discussion  
This study provides several insights into the characteristics of late anthracycline 
cardiomyopathy. First, the primary driver of reduced LVEF in long term 
anthracycline cardiomyopathy was a pathological increase in iLVESV and the 
predominant left ventricular phenotypes were: normal mass and normal volume, 
eccentric dilatation or myocardial atrophy with normal volume. Second, the 
prevalence of focal myocardial fibrosis at a median five years post-therapy was 
relatively low (19%) and distributed exclusively in the mid-myocardium with a 
predilection for the basal and mid-interventricular septum. Third, patients with 
LGE had significantly reduced LVEF compared with those without. Fourth, in 
subgroup analysis, the prevalence of elevated native myocardial T1 
measurements was relatively high (36%) and these patients had significantly 
reduced systolic function (LVEF), adverse left ventricular remodelling and a higher 
rate of hospitalisation for heart failure compared with those with normal native 
myocardial T1 measurements. Fifth, native myocardial T1 measurements and ECV 
correlated with left ventricular volumes, and native T1 also correlated with LVEF 
but ECV did not. 
3.4.1 Cardiac Morphology and Function 
In keeping with previous reports, the predominant mechanism of cardiotoxicity 
in this cohort was a pathological increase in iLVESV82, 110. Both iLVM and iLVEDV, 
as well as all measures of RV volume and systolic function remained within 
established reference ranges172. Interestingly, iLVEDV was towards the upper 
limits of normal in the cohort as a whole but pathologically elevated in the 
subgroup of patients with focal fibrosis by LGE, suggesting that patients who 
exhibit focal fibrosis have a more severe or advanced cardiomyopathy than those 
who do not, though this was not associated with adverse clinical outcomes. In 
addition, a higher iLVM was observed in patients with focal fibrosis compared 
with those without. This elevation in mass is probably  due to eccentric dilatation, 





hypertrophy (defined by a normal iLVEDV and high indexed left ventricular mass). 
Whilst the comparison is not direct, this finding is at odds with a previous report 
correlating lower iLVM with adverse clinical outcomes 104, and may relate to the 
differing timing, methodology and populations of the studies. A recently 
published longitudinal echocardiography study of breast cancer patients 
described a relative increase in indexed left ventricular mass, which was 
sustained at three years follow up173.  In this study, cumulative anthracycline dose 
was not significantly associated with ventricular volumes or systolic function, 
which may relate to the relatively small sample size and use of anthracycline 
doses in the modern clinical therapeutic range.  
It is interesting to note that there was considerable heterogeneity in the left 
ventricular phenotypes, though the majority of the study population displayed 
either a normal left ventricular phenotype (normal iLVEDV and normal LVMi), 
eccentric dilatation (normal LVMi and  elevated iLVEDV), or a phenotype of 
myocardial atrophy (low LVMi and normal iLVEDV), with only a minority (11%) 
exhibiting the so called Grinch syndrome phenotype (low iLVEDV with or without 
a normal LVMi) previously described by a paediatric study using 
echocardiography174. Aside from methodological differences, this may also point 
to differing remodelling between children and adults. 
While native T1 correlated with left ventricular volumes, it did not correlate 
significantly with LVEF, which is counterintuitive. One potential explanation could 
be the influence of LV wall thickness on LVEF, which was not measured in this 
study but could be the topic of future investigations.  
3.4.2 LGE Imaging - focal fibrosis 
Commensurate with previous reports of both early82, 165, and late104 anthracycline 
cardiomyopathy, the prevalence of LGE at a median interval of five years post-
therapy was low. The minority of patients with LGE exhibited significantly higher 
indexed LV volumes and significantly lower LVEF than those without, though no 





with the published anthracycline cardiomyopathy literature to date but 
inconsistent with meta-analysis of non-ischaemic cardiomyopathies as a whole, 
where the presence of LGE predicts adverse cardiovascular outcomes175. The 
absence of this association could in part be due to the low prevalence of LGE and 
small sample size in studies of anthracycline cardiomyopathy to date, but may 
also represent the limitation of this technique to detect the diffuse myocardial 
fibrosis typically associated with anthracycline cardiomyopathy6.  It is noteworthy 
that patients with LGE were assessed after a significantly greater period than 
those without, which raises the question of whether fibrosis develops over time 
and may explain why early studies of anthracycline cardiomyopathy have 
reported such a low prevalence of LGE. However, in univariable regression 
modelling of LGE, time interval between chemotherapy and CMR was not 
significantly associated with left ventricular volumes or any parameters of systolic 
function, therefore it was excluded from the multivariable model. 
While regression analysis controlled for sex and diabetic status, it is difficult to 
completely adjust for these differences in baseline measures. No study has 
reported the prevalence of non-ischaemic LGE in asymptomatic diabetic 
populations for comparison. 
3.4.3 Native myocardial T1 mapping – diffuse fibrosis 
Historically, diffuse myocardial fibrosis has been difficult to detect without the 
inherent risks attached to invasive cardiac biopsy. However, the advent of native 
myocardial T1 mapping and ECV techniques by CMR now permit the 
quantification of diffuse fibrosis non-invasively176 with excellent reproducibility 
and robust validation against biopsy proven collagen volume fraction and 
extracellular space reported in explanted hearts105 and biopsied patients with 
dilated cardiomyopathy106. Two previous studies of anthracycline 
cardiomyopathy in adults have described abnormal elevation of ECV in cancer 
survivors three years108 and seven years107 after anthracycline treatment. The 





and the latter correlated this elevation directly with left atrial volume and 
negatively with diastolic function, and also described higher ECV in patients with 
reduced LVEF, compared with those with preserved LVEF. A further paediatric 
study provided complementary data correlating native myocardial T1 and ECV 
with exercise capacity, anthracycline dose and subtle ventricular remodelling167.  
This study complements this work by demonstrating significant correlations 
between absolute native myocardial T1 measurements, ECV and measures of left 
ventricular volumes and systolic function in anthracycline cardiomyopathy and in 
this regard, provides novel insight. Patients with increased native myocardial T1 
measurements displayed significant adverse left ventricular remodelling and 
reduced systolic function (as measured by LVEF), compared with those with 
normal native myocardial T1 measurements. A greater number of 
hospitalisations occurred in the subgroup with increased native myocardial T1 
measurements. In addition, absolute values of native myocardial T1 and ECV 
correlated significantly with left ventricular volumes and native myocardial T1 
also correlated with LVEF, MAPSE and LAVi, all of which would suggest a greater 
burden of diffuse fibrosis in patients with larger ventricular volumes and worse 
systolic function. Finally, it is noteworthy that 13 (36%) of the subgroup had 
diffuse fibrosis judged by an abnormal native myocardial T1 measurement, but 
only one (8%) of these had coexisting evidence of focal fibrosis when assessed 
qualitatively by LGE. Therefore, relying solely on LGE would have misclassified 
92% of these patients as not having fibrosis. This finding is again in keeping with 
the histopathological report of focal fibrosis in only 10% of explanted hearts with 
anthracycline cardiomyopathy6. CMR T1 techniques appear to offer additional 
insight in anthracycline cardiomyopathy, yet the precise role of these sequences 
as a diagnostic tool, method of monitoring and means of guiding therapy is yet to 







3.4.4 Study limitations 
This was a retrospective single centre study of a small and relatively 
heterogeneous cohort of patients referred for CMR on clinical grounds and, as 
such, the findings should be interpreted in this context and viewed as hypothesis 
generating. The small sample size and low number of events mean that firm 
conclusions, particularly regarding clinical outcomes, cannot be drawn and large, 
prospectively conducted, multicentre studies are warranted to address this area 
of important clinical uncertainty. Native myocardial T1 and T2 mapping 
sequences, and therefore ECV estimation was not available for the entire study 
population due to the introduction of this sequence to the department in 2015. 
However, it is felt that this subgroup provides insight into the utility of this 
sequence in anthracycline cardiomyopathy and the available data were therefore 
included. It is also important to note that for statistical purposes, we chose a 
native myocardial T1 cut off value of the median +1 standard deviation (1064ms) 
to divide groups. This has the potential to include patients with normal range 
native T1 in the ‘elevated’ group. Indeed, this is why this group is not described 
as having ‘abnormal’ native T1 measurements. Furthermore, we performed 
correlative analysis of native T1 as a continuous, rather than dichotomised 
measure. This confirmed significant associations of native myocardial T1 with 
multiple measures of left ventricular volumes and systolic function. Finally, 
complementary echocardiographic, electrocardiographic, blood biomarker 
(Troponin, BNP), and histopathological data were not consistently available and 
the cross sectional design of the study meant that temporal changes could not be 
assessed. A prospective study incorporating these measures prior to, during and 






Late stage anthracycline cardiomyopathy is characterised by pathological 
increase in iLVESV, normal or dilated iLVEDV, low (19%) prevalence of focal septal 
fibrosis identified by LGE, and higher (36%) prevalence of diffuse fibrosis 
identified by elevated native T1 measurements. Both forms of fibrosis were 
associated with adverse left ventricular remodelling and reduced LVEF during the 
follow-up period studied. A higher rate of hospitalisation for heart failure was 
observed in patients with elevated native myocardial T1 mapping measurements. 
3.6 Novel Findings 
1. LGE (surrogate CMR marker of focal fibrosis) is not a common finding 
(19%) in late stage anthracycline cardiomyopathy but its presence is 
associated with adverse left ventricular remodelling and reduced LVEF. 
2. Elevated native myocardial T1 mapping values (surrogate marker of 
diffuse fibrosis) are more common (36%) in late stage anthracycline 
cardiomyopathy and are associated with adverse left ventricular 







Chapter 4 CMR Characterisation of Anthracycline 
Cardiotoxicity in Adults with Normal Left Ventricular 
Ejection Fraction 
4.1 Introduction 
Anthracycline chemotherapy is efficacious but confers excess cardiovascular risk, 
both in the immediate and long term. Current surveillance strategies rely 
principally on the assessment of LVEF to diagnose cardiotoxicity2, 19, 158. However, 
declines in LVEF may only manifest once tissue level damage is extensive, and its 
reliance on geometric assumptions and susceptibility to loading conditions are 
recognised limitations. Consequently, quantification of myocardial deformation 
and non-invasive characterisation of myocardial tissue using CMR have emerged 
as important tools that provide complementary mechanistic insight and may 
facilitate early detection of systolic impairment in patients treated with 
anthracycline.  
CMR studies of childhood cancer survivors have improved our understanding of 
the long term effects of anthracycline on myocardial deformation and myocardial 
tissue composition167, 177, 178, reporting detectable differences in myocardial 
strain, LV mass, native myocardial T1, and ECV. To date, few long term adult 
studies have been conducted and most have either included patients with 
impaired systolic function107, 108, in whom strain and tissue characteristics are 
recognised to be impaired, exclusively enrolled female patients with breast 
cancer55 or neglected to include a control arm179.  
Accordingly, a cross sectional case control study of anthracycline treated cancer 
survivors with normal LVEF was conducted, comparing them to a control 
population of similar age and sex using CMR feature tracking and advanced tissue 
characterisation techniques. It was hypothesised that structural and functional 






4.2.1 Study design and participants 
A retrospective cross sectional study of consecutive patients referred for clinically 
indicated CMR (1.5T) at the centre (Bristol Heart Institute) between March 2012 
and March 2019 was performed. The study enrolled patients age > 18 years with 
normal LVEF who had been treated with anthracycline. Patients were not eligible 
if they had co-existing cardiac disease (e.g. myocardial infarction, significant 
valvular heart disease, cardiomyopathy), contraindications to CMR, or if 
anthracycline treatment had been administered within the past three months.  
Forty-five patient controls of similar age and sex distribution, with normal resting 
electrocardiogram, and normal CMR findings (normal cardiac volumes and LVEF, 
absence of myocardial oedema and LGE) served as controls. Indications for 
clinical CMR in patient controls included: assessment of palpitations when echo 
was equivocal or not diagnostic (n=18), atypical anginal chest pain (n=15), family 
history of cardiomyopathy (n=9), and investigation of hypertension (n=3). All 
participants provided written consent for use of anonymised data for research 
purposes at the time of CMR. Formal Research Ethics Committee (REC) approval 
was not obtained. The local institutional research and innovation department 
(Bristol Royal Infirmary) approved the study as a service evaluation exercise. The 
research team designed the study, gathered and analysed the data and vouch for 
data fidelity.  
4.2.2 CMR   
4.2.2.1 Left ventricular volumes, ejection fraction and strain  
Patients underwent CMR on a single 1.5 Tesla system (Avanto, Siemens, Erlangen, 
Germany). Short axis steady state free precession cines (typical parameters: 8mm 
slice thickness [no gap], temporal resolution 38.1 ms, echo time 1.07 ms, in plane 
pixel size 1.5 x 0.8 mm) of the left ventricle were used to measure left ventricular 
(LV) volumes, ejection fraction (EF) and mass by drawing epicardial and 





indexed to body surface area, according to established methods180, 181. Global 
longitudinal (GLS), global circumferential (GCS) and global radial strain (GRS) 
parameters were calculated from short and long (two, three and four chamber) 
axis cines using feature tracking post-processing software (CMR42, Circle 
Cardiovascular Imaging, Calgary, Canada) in two (2D) and three dimensions (3D). 
4.2.2.2 Native myocardial T1 mapping, ECV and indexed myocardial cell 
volume 
MOLLI recovery sequences170 (35° flip angle, 100ms minimum TI, 80 ms TI 
increment, 150 ms time delay with 5-(3)-3 heartbeat acquisition scheme) 
provided motion corrected, short axis native myocardial T1 maps of the mid-
ventricular septum, on which a region of interest was drawn to determine native 
myocardial T1 measurements. ECV was calculated using the established 
formula153: ECV = (1-haematocrit) x (∆R1 myocardium/∆R1blood) with the 
4(1)3(1)2 MOLLI variant. Indexed myocardial volume was calculated by dividing 
indexed LV mass by myocardial specific gravity 1.05 g/ml. Myocardial cell volume 
fraction was calculated, as previously described182, as (1-ECV), and multiplied by 
indexed myocardial volume to estimate indexed myocardial cell volume. This 
technique has previously demonstrated excellent reproducibility183. 
4.2.2.3 Reproducibility 
Two experienced CMR readers (IH, BB) blinded to all study data, independently 
analysed 10 anthracycline treated patients in random order to provide 
interobserver reproducibility data. These 10 anthracycline treated patients were 
re-analysed in a blinded random order four weeks later by IH to provide intra-
observer reproducibility data. 
4.2.3 Data analysis 
Statistical analysis was performed using SPSS (SPSS version 24, Armonk, United 
States of America: IBM Corp.). Data are presented as mean ± standard deviation 
for continuous variables; counts and percentages for categorical variables. 





Whitney U test for normally and non-normally distributed data, respectively. 
Intra- and interobserver reproducibility was assessed using intraclass correlation 
coefficient (ICC) and coefficients of variation (CoV). The CoV was calculated as the 
standard deviation of the differences, divided by the mean. ICCs were defined as 
poor (≤ 0.49), moderate (0.5-0.74), good (0.75-0.89) or excellent (≥ 0.9). A p value 
of < .05 was considered significant.  
4.3 Results 
4.3.1 Patient characteristics 
Baseline demographic data of all participants are displayed in Table 4-1. The 
mean age (53 ± 16 vs. 56 ± 16 years, p = .3) and sex distribution (60% female vs. 
60% female, p = 1.0) were similar in each group, as were the body surface area 
and medical history. The only statistically significant difference between the 
groups was the haematocrit, which was significantly lower in anthracycline 
treated patients, compared with controls (36 ± 7 vs. 41 ± 3%, p < .001). The 
majority of patients were treated for haematological malignancy (n = 33; 73%), 
or breast cancer (n = 10; 22%), received a mean doxorubicin equivalent dose of 
237 ± 83 mg/m2, and underwent CMR at a median interval of 11 (range 3-36) 
months after completion of anthracycline treatment. The interval between 
completion of anthracycline treatment and CMR did not correlate with cardiac 
volumes, systolic function or myocardial tissue characteristics. However, after 
adjusting for age and sex, regression analysis revealed a weak but statistically 
significant negative association between anthracycline dose and indexed 
myocardial cell volume (r = -0.31, p  = .02; Figure 4-1). Radiotherapy was 
administered to a minority (n = 9, 20%) and there were no significant differences 
in any of the measured parameters between those who did and did not receive 





Table 4-1 Demographic data 
 Controls  
(n = 45) 
Anthracycline 
treated patients 
(n = 45) 
p 
Mean age (years) 53 ± 16 56 ± 16 .3 












Mean body surface area (m2) 1.92 ± 0.24 1.89 ± 0.24 .62 
Mean body mass index (kg/m2) 27.2 ± 5.7  26.7 ± 5.8 .69 

















 Mean DOX (mg/m2) 
 Median interval (months) 














237 ± 83 
11 (3 – 36) 
9 (20) 
 
Haematocrit (%) 41 ± 3 36 ± 7 < .001 
Plus-minus values are means ± SD. - = interquartile range. DOX = doxorubicin 






Figure 4-1 Linear regression analysis of myocardial cell volume and doxorubicin dose 
Linear regression analysis adjusting for age and sex demonstrating a significant negative association between indexed equivalent 






4.3.2 Ventricular volumes and ejection fraction 
Left ventricular end diastolic volume indexed (LVEDVi) (69.2 ± 14.8 vs. 72.2 ± 10.3 
ml/m2, p = .26) left ventricular end systolic volume indexed (LVESVi) (28.6 ± 8.0  
vs. 28.3 ± 4.83 ml/m2), and LVEF (59.5 ± 4.1 vs. 60.8 ± 2.4%, p = .07) were similar 
between anthracycline treated patients and controls, respectively. Indexed right 
ventricular end diastolic volume (66.8 ± 14.6 vs. 72.7 ± 14.1ml/m2, p = .06), 
indexed right ventricular end-systolic volume (27.4 ± 7.0 vs. 30.4 ± 9.5 ml/m2, p = 
.09), and right ventricular ejection fraction (59.0 ± 5.7 vs. 59.0 ± 7.0%, p = .96) 
were also similar for anthracycline treated patients and controls, respectively. 
However, MAPSE was significantly reduced in anthracycline treated patients 
compared with controls (13.5 ± 3.0 vs. 14.7 ± 2.4mm, p = .04, Figure 4-2) but 
tricuspid annular plane systolic excursion (TAPSE) was not (21.7 ± 4.1 vs. 22.9 ± 






Figure 4-2 Comparison of functional parameters between anthracycline treated patients (cases) and controls 
Box and whisker plots comparing functional parameters (2D feature tracking GLS, 3D feature tracking GLS and MAPSE) demonstrating 
statistically significant differences assessed by unpaired t tests. In each example, cases display statistically significant impairment, 










































4.3.3 Feature tracking strain 
2D GCS (-21.1 ± 2.6 vs. -21.9 ± 2.4%, p = .18), 2D GRS (42.8 ± 9.5 vs. 43.8 ± 10.3%, 
p = .61), 3D GCS (-17.7 ± 2.8 vs. -18.8 ± 2.8%, p = .07), and 3D GRS (42.6 ± 11.4 vs. 
45.8 ± 10.4 %, p = .16) were similar between anthracycline treated patients and 
controls, respectively. However, both 2D GLS (-18.3 ± 2.6 vs. -20.0 ± 2.0%, p <.001) 
and 3D GLS (-14.5 ± 2.3 vs. -16.4 ± 2.6%, p < .001) were significantly impaired in 
anthracycline treated patients, compared with controls (Figure 4-2). 
4.3.4 Tissue characterisation  
Native myocardial T1 was significantly higher in anthracycline treated patients, 
compared with controls (1021 ± 40 vs. 996 ± 35ms, p = .002), and ECV was 
significantly higher in anthracycline treated patients, compared with controls 
(29.5 ± 4.5 vs. 27.4 ± 2.3%, p = .006) Figure 4-3. No anthracycline treated patients 
or controls had any segments of LGE. There was no significant difference in native 
T1 or ECV between males and females (p = .126 and .197, respectively). In 
addition, there was nod ifference in  
4.3.5 Left ventricular mass and myocardial cell volume  
Indexed left ventricular mass (LVMi) was significantly smaller in anthracycline 
treated patients compared with controls (45.6 ± 8.7 vs. 50.3 ± 10.1 g/m2, p =.02, 
Figure 4-3). Furthermore, indexed myocardial cell volume was significantly lower 
in anthracycline treated patients, compared with controls (30.5 ± 5.7 vs. 34.8 ± 







Figure 4-3 Comparison of tissue parameters between anthracycline treated 
patients (cases) and controls 
Box and whisker plots comparing tissue parameters (LV mass indexed, 
indexed myocardial cell volume, native myocardial T1 and extracellular 
volume fraction (ECV)), which demonstrate statistically significant differences 
between anthracycline treated patients (cases) and controls. Median, 
interquartile range, 95% confidence intervals and outliers (black dots and 















































Excellent interobserver reproducibility of 2D GLS, 3D GCS, 3D GRS, native T1 and 
ECV was demonstrated, with 2D GCS and 2D GRS showing good reproducibility, 
and only 3D GLS showing moderate reproducibility (Table 4-2). Intra-observer 
reproducibility of all parameters was universally excellent (Error! Reference 
source not found.). 
Table 4-2 Interobserver reproducibility of parameters 
Parameter MD SD ICC (95%CI) CoV (%) 
2DGLS 0.05 1.29 0.93 (0.72 – 0.98) -4.2 
2DGCS -0.84 2.00 0.86 (0.42 – 0.96) -4.4 
2DGRS 2.40 5.19 0.88 (0.55 – 0.97) 6.6 
3DGLS 0.08 2.1 0.71 (0.18 – 0.93) -7.6 
3DGCS -0.03 0.51 0.98 (0.94 – 0.99) -1.7 
3DGRS -0.93 3.06 0.98 (0.93 – 0.99) 3.5 
Native T1 5.4 16.1 0.93 (0.71 – 0.98) 0.8 
ECV 0.21 1.56 0.92 (0.71 – 0.98) 3.3 
MD = mean difference, SD = standard deviation, ICC = intraclass correlation 
coefficient, CI = 95% confidence interval, CoV = coefficient of variation, 2D = 
two dimensional, 3D = three dimensional, GLS = global longitudinal strain, GCS 







Table 4-3 Intra-observer reproducibility of parameters 
Parameter MD SD ICC (CI) CoV (%) 
2DGLS 0.27 0.68 0.98 (0.90 – 0.99) -2.3 
2DGCS 0.11 0.93 0.97 (0.90 – 0.99) -1.9 
2DGRS -0.89 3.9 0.93 (0.72 – 0.98) 2.7 
3DGLS -0.5 0.94 0.95 (0.79 – 0.99) -4.9 
3DGCS -0.2 0.72 0.97 (0.89 – 0.99) -2.0 
3DGRS 1.2 1.74 0.98 (0.97 – 0.99) 2.4 
Native T1 1.9 12.2 0.96 (0.84 – 0.99) 0.6 
ECV 0.9 1.1 0.97 (0.87 – 0.99) 2.2 
MD = mean difference, SD = standard deviation, ICC = intraclass correlation 
coefficient, CI = 95% confidence interval, CoV = coefficient of variation, 2D = 
two dimensional, 3D = three dimensional, GLS = global longitudinal strain, GCS 








This study investigated structural and functional myocardial changes in 
anthracycline treated cancer survivors with normal range LVEF at a median follow 
up interval of 11 months compared with a healthy control population of similar 
age and sex. Four important findings are reported. First, several measures of 
longitudinal systolic function (MAPSE, 2D GLS and 3D GLS) are significantly 
impaired in anthracycline treated cancer survivors, as compared with controls in 
the presence of normal LVEF. Second, LV mass and myocardial cell volume are 
significantly reduced in anthracycline treated cancer survivors. Third, surrogate 
CMR markers of myocardial fibrosis and extracellular expansion (native 
myocardial T1 and ECV) are significantly elevated in cancer survivors. Fourth, 
these imaging biomarkers show good to excellent levels of inter- and intra-
observer reproducibility.  
4.5.1 Systolic function 
While LVEF is the most widely used non-invasive parameter to monitor cardiac 
function in patients receiving cardiotoxic therapy, tissue level damage may 
already be extensive by the time a change in LVEF is detected, and limitations 
include reliance on geometric assumptions and the influence of loading 
conditions. Consequently, semi-automated techniques that track myocardial 
deformation to quantify strain have emerged as powerful tools to appraise 
systolic function49. Echocardiography derived strain is well established, whereas 
evidence for CMR derived strain in cardio-oncology populations is comparably 
limited and furthermore, partitioned by different strain techniques. It is reported 
that GLS is an early marker of systolic dysfunction and may deteriorate prior to 
asymptomatic declines in LVEF49.  Our findings support this hypothesis by 
demonstrating that CMR feature tracking GLS is impaired in long term 
anthracycline treated cancer survivors, compared with controls, in the setting of 





Several prospective adult studies have reported detectable reductions in 
components of 2D CMR strain using various techniques during the acute phase 
of anthracycline treatment 82, 84, 102, 118. This comparatively large study of feature 
tracking strain in anthracycline treated adult cancer survivors complements this 
work by confirming persisting long term changes, and replicates similar results 
from survivors of childhood cancer with normal LVEF177. One previous 
prospective adult study of 10 patients with a mean post-treatment LVEF of 52.8% 
reported significant reduction of both CMR 2D GCS and 2D GLS at three months, 
compared with healthy controls. Similar results were found for 2D GLS but the 
findings for GCS were not replicated, which have also been reported by other 
groups84. These discrepancies are probably accounted for by different 
populations (mean LVEF was higher at 59.5% in this study), methodologies (strain 
technique, hardware and software), and follow up intervals. Furthermore, and to 
the best of our knowledge, no published CMR studies of 3D strain in the context 
of anthracycline treatment exist. While there are inherent differences between 
CMR derived and echocardiography derived strain184, the results are broadly in 
line with an echocardiographic study reporting the potential utility of 3D based 
techniques in a breast cancer population185. Santoro et al. reported that while 3D 
strain was potentially superior to 2D methods, it was only feasible in 60% of 
patients due to the effects of age, BMI, radiotherapy, left mastectomy and breast 
prostheses on image quality. By contrast, 3D strain was feasible in our entire 
cohort.  However, it should be noted that the only parameter that exhibited a 
statistically significant reduction in patients (3D GLS) also showed the lowest 
interobserver reproducibility (ICC 0.71) and has no established normal reference 
range. Therefore, CMR derived 3D GLS continues to be a research tool. All of 
which highlights the requirement for large, robust, longitudinal research to 
delineate the role of CMR based strain techniques, particularly with respect to 
prognosis and clinical outcomes, which in other cardiovascular populations have 






4.5.2 Tissue characterisation 
The advent of native T1 and ECV techniques furnish the unique ability to quantify 
interstitial myocardial fibrosis non-invasively with excellent reproducibility and 
robust validation against biopsy proven collagen volume fraction and 
extracellular space105, 106. Previous studies of anthracycline treated survivors of 
childhood cancer have reported conflicting results. Some studies reported 
significant, detectable changes in native T1 and ECV as compared with controls 
at mean follow up intervals of 7.6167 and 9.6 years177, whereas others did not178, 
with female sex reported to contribute to elevated values. Long term adult 
studies have reported elevated native T1 and ECV in the context of LVEF 
impairment107, 108 with conflicting data in the presence of normal LVEF108, 179, 
though the latter study lacked a control arm and included 26 breast cancer 
patients treated with trastuzumab, of whom only 62% received anthracycline. 
Native myocardial T1 and ECV values in this study were comparable to those 
reported by other groups107, 108, 186 and further evidence of statistical differences 
in native T1 and ECV in adult populations with normal LVEF is provided. However, 
further research is required to determine the precise role and utility of these 
imaging biomarkers for evaluating patients treated by potentially cardiotoxic 
therapy, and whereas their relationship with cardiovascular outcomes and ability 
to risk stratify in other disease states has recently been described187, this is yet to 
be replicated in cardio-oncology populations. It is also worth noting that 
significant baseline differences in haematocrit partly contributed to the 
difference in ECV, though significant differences in native myocardial T1 
measurements argue in favour of a significant difference beyond haematocrit. 
4.5.3 Left ventricular mass and myocardial cell volume 
LV mass loss following anthracycline treatment has previously been reported by 
studies generally composed of patients with impaired LVEF 104, 108, 113, and has 
been associated with worsening heart failure symptomatology188 and major 
adverse cardiac events104. A recent study of 27 women with normal baseline LVEF 





provided additional insight into the underlying composition of the myocardium 
by prospectively documenting a reduction in LV cardiomyocyte mass, purported 
to represent cardiomyocyte atrophy55, which correlated with the degree of 
myocardial injury quantified by troponin elevation. The results support these 
findings and extend this observation to adult cancer survivors with normal range 
LVEF, in whom indexed myocardial cell volume was significantly lower than a 
control population. Furthermore, the degree of myocardial atrophy (represented 
by indexed myocardial cell volume) was shown to be inversely associated with 
anthracycline dose, even using modern dose capped regimens (Figure 1). 
4.5.4 Reproducibility 
Previous studies of patients receiving chemotherapy have reported high levels of 
inter- and intra-observer reproducibility for native T1, ECV, and 2D feature 
tracking strain186. However, this is the first study to combine the assessment of 
tissue characteristics and strain parameters, and the first to report the 
reproducibility of 3D feature tracking CMR strain in the context of anthracycline 
treatment. Overall, higher levels of intra-observer, compared with inter-observer 
reproducibility were noted and therefore, it may be prudent for the same reader 
to re-measure values from different timepoints for the purpose of serial 
evaluation. Whilst reproducibility of parameters is high, recent evidence of 
significant temporal variability and recognised overlap with healthy controls186 
continues to represent a barrier to incorporation in routine clinical practice. 
Adoption of automated analysis and artificial intelligence may be one method to 
improve reproducibility, pending confirmatory data. 
4.5.5 Study limitations 
The cross sectional design of the study precludes assessment of temporal 
changes in individuals treated with anthracycline, or their relationship with major 
adverse cardiovascular events, such as heart failure hospitalisation or mortality.  
The data were obtained at rest and as such, do not provide information on the 
functional or exercise capacity of patients, compared with controls, which may 





assessment of exercise capacity could address these limitations. In addition, the 
study used specific hardware and software to collect and analyse data, which 
impacts the external validity of the results to other populations and clinical 
systems, and should be borne in mind when interpreting the results. The addition 
of another group of patients with impaired LVEF would also be of of additional 
value and could be a focus for future work.  
4.6 Conclusion 
Anthracycline treated cancer survivors with a normal LVEF have significant 
perturbations of CMR derived GLS (2D and 3D), native myocardial T1, ECV, 
indexed LV mass and indexed myocardial cell volume, compared with a control 
population of similar age and sex (Figure 4-4). These parameters display good to 
excellent levels of inter- and intra-observer reproducibility.  Therefore, CMR 
feature tracking strain and advanced tissue characterisation techniques may have 
a role to play in the evaluation of long term anthracycline cardiotoxicity by 
providing complementary discriminatory information to traditional LVEF focused 
techniques.  
4.7 Novel findings 
1. Anthracycline treated cancer survivors with a normal LVEF have 
significant perturbations of GLS (2D and 3D), native myocardial T1, ECV, 
indexed LV mass and indexed myocardial cell volume, compared with a 
control population of similar age and sex, which are readily detectable by 
CMR. 
2. Indexed myocardial cell volume, which serves as a marker of 
cardiomyocyte loss, is inversely associated with anthracycline dose, even 






Figure 4-4 Representative case examples 
Native myocardial T1 and ECV maps (top row), 2D feature tracking GLS curves and bSSFP cine images at end systole with myocardial strain overlay 
(bottom row). Regions of interest are drawn on the mid interventricular septum of the maps (blue crescents) to quantify native myocardial T1 (left 
column) and ECV (right column). LVEF = left ventricular ejection fraction, iLVM = indexed left ventricular mass, iMCV = indexed myocardial cell volume, 





Chapter 5 Prospective Multiparametric CMR 
Characterisation and MicroRNA Profiling of 
Anthracycline Cardiotoxicity: A Pilot Study 
5.1 Introduction 
Anthracycline chemotherapy provides effective treatment for several forms of 
cancer but its use is mitigated by dose dependent cardiotoxicity189.  
Consequently, societal guidelines recommend serial monitoring of LVEF with 
cardiac imaging in patients receiving these regimens2, 19, 158.  
Mitochondrial oedema and intracardiomyocyte vacuolisation are the 
histopathological hallmarks of early anthracycline cardiotoxicity4, 190 but 
importantly, these changes seem to predate myocardial functional changes4. 
Indeed, tissue level damage may already be extensive by the time a change in 
LVEF is detected. The later stages of cardiotoxicity are characterised by cell death, 
replacement fibrosis6 and an adverse prognosis7.  
Contemporary dose capped  regimens mean that cardiotoxicity affects 
approximately 9% of patients20. Furthermore, recovery of LVEF following 
anthracycline is unpredictable, with only a minority of patients returning to 
baseline systolic function20. Identifying cardiotoxicity early and instituting 
protective therapy reduces cardiovascular adverse events36 and facilitates 
therapeutic efficacy. Notwithstanding the recognition of contributory clinical risk 
factors such as age, female sex, pre-existing cardiovascular disease19, 158 and 
genetic predisposition191, predicting individual susceptibility to anthracycline 
cardiotoxicity continues to pose a significant challenge. All of which underscores 
the need for of an accurate, reproducible, non-invasive biomarker that can 
identify cardiotoxicity at an early stage.  
CMR is the reference standard method to assess cardiac anatomy and function77, 





characterise myocardial tissue non-invasively. The ability of CMR to detect 
myocardial oedema and fibrosis with native T2, and T1 mapping sequences, 
respectively was recently validated histopathologically in a porcine model of 
anthracycline cardiotoxicity5. However, to date, few adult human studies have 
used prospective CMR to catalogue the cardiac effects of anthracycline 82, 93, 102, 
110, 192 and fewer still have included multiparametric mapping techniques120, 193. 
Circulating microRNAs (miRNA) are short non-coding RNAs that regulate 
elemental cellular processes and play a critical role in cardiovascular biology65. 
Their relative stability and ease of quantification, combined with high levels of 
sensitivity and specificity, make them an appealing biomarker in several 
cardiovascular disease states, with emerging animal67 and latterly human 
models68, 70 confirming temporal dysregulation in the context of anthracycline 
cardiotoxicity. 
Accordingly, the objective of this pilot study was to prospectively characterise 
anthracycline cardiotoxicity and explore the ability of multiparametric CMR and 
miRNA to predict recovery of LVEF following completion of anthracycline 
chemotherapy. 
5.2 Methods 
From April 2017 to August 2018, 24 patients were prospectively enrolled at two 
haematology centres in Bristol, United Kingdom: Bristol Haematology and 
Oncology Centre and Southmead Hospital. The study was approved by the West 
Midlands - Solihull Research Ethics Committee. All participants provided written 
informed consent. 
The study enrolled consecutive patients age > 18 with a new diagnosis of high 
grade non-Hodgkin (NHL) and Hodgkin lymphoma (HL) scheduled for > 6 cycles of 
anthracycline, or acute myeloid leukaemia (AML) scheduled for full dose 





prior cardiac disease or malignancy, prior chemotherapy, or had 
contraindications to CMR (ferromagnetic foreign body, claustrophobia, severe 
renal impairment [eGFR < 30 ml/min/1.73m2]).  
CMR, transthoracic echocardiography, electrocardiogram (ECG), serum 
biomarkers (including miRNAs and Troponin I [TnI]) and symptom enquiry were 
performed on the same day at three time points: at baseline, on completion of 
chemotherapy, and six months after completion of chemotherapy. Three 
patients were withdrawn between baseline and completion of chemotherapy 
(two deaths, one lost to follow up) and another four between completion of 
chemotherapy and six month follow up (three deaths, one lost to follow up; 
Figure 5-1), giving a total of 17 patients with complete assessments. In secondary 
analysis, these 17 patients were divided into tertiles according to recovery of 
LVEF between completion of chemotherapy and six month follow up. Predictors 
of LVEF recovery were explored from baseline and completion of chemotherapy 
visits. 
The research team designed the study, gathered and analysed the data, prepared 
the manuscript, and vouch for data fidelity. Blinded, random order analysis of 
anonymised imaging data was undertaken at the end of the study. Data was 
collected and managed using Research Electronic Data Capture (REDCap)194, 







Figure 5-1 Study enrolment and follow up
87 patients with newly diagnosed haematological 
malignancy screened for eligibility
2 died due to progressive haematological malignancy 
1 lost to follow up
3 died due to progressive haematological malignancy 
1 lost to follow up
6 months after 
completion of 
chemotherapy 




Each Study Visit Comprised:
Symptom enquiry and clinical exam
ECG, Echocardiography and CMR
Blood testing (incl. microRNA, TnI)
Baseline
(n = 24)
63 were not eligible
23 Had prior history of malignancy or chemotherapy
16 Had prior history of cardiac disease
12 Were too unwell to participate
9 Declined to participate
2 Had severe kidney disease (eGFR < 30ml.min-1)







5.2.1 CMR  
5.2.1.1 Left ventricular volumes, ejection fraction and strain  
Patients underwent CMR at 1.5 Tesla (Avanto, Siemens, Erlangen, Germany). 
Short axis steady state free precession cines (typical parameters: 8mm slice 
thickness [no gap], temporal resolution 38.1 ms, echo time 1.07 ms, in plane pixel 
size 1.5 x 0.8 mm) of the left ventricle were used to measure left ventricular (LV) 
volumes, ejection fraction (EF) and mass by drawing epicardial and endocardial 
borders at end systole and end diastole. Measurements were indexed to body 
surface area, according to established methods168. Average global longitudinal, 
circumferential, and radial strain parameters were calculated from short and long 
(two, three and four chamber) axis cines using voxel tracking post-processing 
software. Lateral MAPSE was measured in the four chamber view (CMR42, Circle 
Cardiovascular Imaging, Calgary, Canada). 
5.2.1.2 Native myocardial T1 mapping, T2 mapping and ECV  
MOLLI recovery sequence170 (35° flip angle, 100 ms minimum TI, 80 ms TI 
increment, 150 ms time delay with 5-(3)-3 heartbeat acquisition scheme) was 
used to obtain a motion corrected, short axis native myocardial T1 map of the 
mid ventricular septum, on which a region of interest was drawn to determine 
native myocardial T1 measurements. A blood sample was taken immediately 
prior to CMR to determine Troponin I and haematocrit (Abbott Laboratories, 
United States). The latter allowed calculation of ECV using the established 
formula153: ECV = (1-haematocrit) x (R1 myocardium/R1blood). Post-contrast T1 
maps were obtained with the 4(1)3(1)2 MOLLI variant. Short axis mid ventricular 
T2 maps were obtained using a T2 prepared steady state free precession 
sequence (223.77/1.12; 70° flip angle, section thickness 8 mm; field of view, 340-
400 mm; matrix 156x192; voxel size 2.3 x 1.9 x 8 mm), on which a region of 
interest was drawn to determine native myocardial T2 measurements, using 
Argus software (Siemens Healthineers, Germany). 





Echocardiograms were performed by two fully accredited researchers using a 
single Epiq machine (Philips, Netherlands). Biplane 2D LVEF was calculated using 
Simpson’s rule from apical four and two chamber images and 3D LVEF using semi-
automated software (HeartModel, Philips, Netherlands). GLS was measured by 
tracing three fiducial landmarks (apex, lateral and medial mitral annulus) on the 
endocardial border with automated function imaging (Automated Cardiac 
Motion Quantification [aCMQ], Philips, Netherlands). The fidelity of contours to 
cardiac motion was tracked through the cardiac cycle and manually adjusted, if 
necessary. Measures were not recorded if there was inadequate visualisation of 
 3 contiguous myocardial segments. 
5.2.3 Electrocardiography 
A 12 lead surface electrocardiogram (ECG) was obtained at each study visit and 
assessed for abnormalities of rhythm, conduction intervals, ST and T wave 
morphology. 
5.2.4 Serum Troponin I and miRNAs 
Blood was drawn at each study visit. Troponin I (TnI) was determined at the 
bedside (Abbott Laboratories, United States of America). Platelet poor plasma 
was prepared by drawing blood into a sodium citrate vacutainer and centrifuging 
at 2240 g for 10 minutes at room temperature. The plasma supernatant was 
removed to a fresh tube without disturbing the buffy coat and centrifuged again 
at 2240 g for 10 minutes at room temperature. The supernatant was removed to 
a fresh Eppendorf LoBind microcentrifuge tube and stored at -80°C195. RNA 
extraction, small RNA sequencing and data QC and alignment were performed on 
completion of the study by Qiagen (Germany) on samples obtained prior to, and 
on completion of chemotherapy. Differential expression analysis (likelihood ratio 
test following false discovery rate (FDR) correction) comparing circulating miRNA 
expression in patients in tertile 1 (poor LVEF recovery) with tertile 3 (good LVEF 
recovery) was performed in R using the edgeR package196, 197. A miRNA was 





5.2.5 Data analysis 
Data from the 17 patients who completed all visits were divided into tertiles 
according to LVEF recovery between completion of chemotherapy and six month 
follow up. Predictors of LVEF recovery were explored from baseline and 
completion of chemotherapy visits. Overall data are presented as mean ± 
standard deviation for continuous variables; counts and percentages for 
categorical variables. Paired analysis (Wilcoxon signed rank test) was used to 
assess temporal changes. Following rejection of a Kruskal-Wallis test, post hoc 
Dunn’s pairwise comparison was used in secondary analysis to explore predictors 
of left ventricular recovery, comparing tertiles, as defined above. Associations 
between variables were assessed with linear regression. Based on the available 
literature82, 93, 102, a target sample size of 14 was calculated to give 90% power at 
an alpha level of 0.016 to detect a statistically significant change in LVEF of 6.2%. 
Statistical analysis was performed using Stata (Stat version 13, StatCorp LLC, 
United States) with a p value of < .05 considered significant. 
5.3 Results  
5.3.1 Patient characteristics 





Table 5-1. The mean age was 56 years (range 18 to 75). One patient was newly 
diagnosed with one segment of subendocardial LGE in keeping with previously 
unrecognised myocardial infarction at baseline. All patients had normal baseline 
LVEF and GLS on CMR and echocardiography. Patients received anthracycline at 
a mean total doxorubicin equivalent dose of 272 mg/m2 (range 112 to 412). 
Nineteen patients (79%) received a monoclonal antibody, and fourteen (58%) 






Table 5-1 Baseline data 
  (n = 24) 
Mean age (range), years 56 (18-75) 
Male n (%) 





 Mixed race (Black/White) 
 Middle Eastern 
 
22 (92)  
 1 (4)  
1 (4) 
Mean body surface area, (m2) 1.91 ± 0.22 
Mean body mass index, (kg/m2) 26.1 ± 4.8 
NYHA Class I, n (%) 24 (100) 




 Current Smoker 
 Ex-Smoker 








Cardiovascular medications, n (%) 
 Angiotensin converting enzyme inhibitor 
 Angiotensin II receptor blocker  







Haematological diagnosis, n (%) 
 Acute myeloid leukaemia 
 Non-Hodgkin lymphoma  





Chemotherapy, n (%) 
Anthracycline 
 Idarubicin  
 Daunorubicin 
 Doxorubicin 
Mean Doxorubicin equivalent dose (range), mg/m2 
Monoclonal antibody 
 Rituximab 









272 (112 - 412) 
19 (79) 
12 (50) 




Radiotherapy, n (%) 
 Cumulative radiation dose (Gy) 
2 
21 ± 13 






LVEDVi did not change between any timepoint (Table 5-2). LVESVi increased 
significantly between baseline (31 ± 11 ml/m2) and completion of chemotherapy 
(35 ± 9 ml/m2, p < .001), and decreased significantly between completion of 
chemotherapy and six month follow up (32 ± 6 ml/m2, p = .014),  with no 
difference between baseline and six month follow up (p = .89). LVEF was normal 
(61 ± 3%) at baseline, decreased significantly on completion of chemotherapy (53 
± 3%, p < .001), increased significantly at six month follow up (55 ± 3%, p = .018) 
but remained significantly decreased compared with baseline (p < .001). MAPSE 
decreased significantly from baseline to six month follow up (14.0 ± 2.6 to 12.5 ± 
2.4 mm, p = .048) and RVEF also decreased significantly between baseline (60 ± 
6%) and completion of chemotherapy (56 ± 6, p = .005), before partially 
recovering at 6 months (59 ± 1, p = 0.47) . One patient met the criteria for 
cardiotoxicity  (> 10% absolute percentage drop in LVEF to a value < 53%19) on 
completion of chemotherapy, which recovered by six month follow up. All 
measures of 2D feature tracking (FT) CMR strain worsened significantly on 
completion of chemotherapy, compared with baseline (p < .001 in all cases; Table 
5-2). All measures of 2D FT strain worsened significantly between completion of 
chemotherapy and six month follow up (p < .05), but of all FT CMR strain 
parameters, only 2D GLS was persistently impaired at six month follow up (-19.0 
± 2.6%), compared with baseline (-21.1 ± 3.1, p =  .002). 
No significant temporal changes in native myocardial T1 measurements or ECV 
were observed during the study (Table 5-2). Native myocardial T2 measurements 
increased significantly from baseline to completion of chemotherapy (54.0 ± 4.6 
to 57.8 ± 4.9 ms, p = .001) but no other significant between visit differences were 
recorded. Furthermore, neither the absolute native myocardial T2, nor the 
change in native myocardial T2 between baseline and completion of 
chemotherapy correlated with any parameters of left ventricular systolic 
function. No new LGE was observed during the study. Indexed left ventricular 





Table 5-2 Temporal changes in CMR, echocardiographic, serum and physiological metrics 
 Visit 1 
n=24 








Δ V1-3    p 
value 
CMR 
 LVEDVi (ml/m2) 
 LVESVi (ml/m2) 
 LVEF (%) 
 MAPSE (mm) 
 LAVi (ml/m2) 
 LVMi 
 RVEF (%) 
 2D GLS (%) 
 2D GCS (%) 
 2D GRS (%) 
 3D GLS (%) 
 3D GCS (%) 
 3D GRS (%) 
 Myocardial T1 (ms)  
 Myocardial T2 (ms) 
 ECV (%) 
 
77 ± 19 
31 ± 11 
61 ± 3 
14.0 ± 2.6 
45 ± 12 
46 ± 9 
60 ± 6 
-21.1 ± 3.1 
-23.7 ± 3.3 
55.2± 11.6 
-12.9 ±3.2 
-18.9 ± 3.0 
51.8 ±16.7 
1048 ± 33 
54.0 ± 4.6 



















74 ± 15 
35 ± 9 
53 ± 3  
13.0 ± 3.0 
41 ± 10 
47 ± 7 
56 ± 6 
-17.8 ± 2.5 
-21.1 ± 3.5 
44.7 ± 8.8 
-12.3 ± 3.4 
-17.0 ± 3.0 
40.2 ±11.5 
1055 ± 35 
57.8 ± 4.9 



















72 ± 14 
32 ± 6 
55 ± 3 
12.5 ± 2.4 
43 ± 9 
44 ± 7 
59 ± 6 
-19.0 ± 2.6 
-22.5 ± 2.8 
49.9 ± 9.0 
-14.1 ± 2.9 
-16.9 ± 9.3 
47.3 ±13.1 
1055 ± 36 
55.3 ± 3.7 






















 T2 SI ratio (ms) 1.7 ± 0.5 0.053 2.1 ± 0.7 0.03 1.9 ± 0.5 0.07 
Echocardiography 
 2D LVEF (%) 
 3D LVEF (%) 
 GLS (%) 
 
62 ± 3 
61 ± 4 






60 ± 7 
57 ± 4 






59 ± 4 
60 ± 4 






 TnI (pg/ml) 
 Hb (g/dL) 
 Haematocrit (%) 
 eGFR (ml/min/1.73m2) 
 CRP  
 
4.3 ± 13.2 
11.8 ± 2.7 
35 ± 8 
83 ± 27 









11.0 ± 2.5 
26 ± 15  
94 ± 31 








6.9 ± 6.0 
12.9 ± 2.2 
36 ± 11 
104 ± 55 








 Body mass (kg) 
 HR (bpm) 
 SBP (mmHg) 
 DBP (mmHg) 
 
76 ± 15 
79 ± 12 
131 ± 15 







74 ± 14 
74 ± 9 
128 ± 12  







75 ± 16 
74 ± 8 
123 ± 22 






Values are mean ± standard deviation or n (%). 2D = Two dimensional, 3D = Three dimensional, CMR = Cardiovascular magnetic resonance, CRP = C reactive protein, DBP = Diastolic blood 
pressure, ECV = extracellular volume fraction, GLS = Global longitudinal strain, GCS = Global circumferential strain, GRS = Global radial strain, Hb = Haemoglobin, HR = Heart rate, LAVi = Left 
atrial volume indexed, LVEDVi = Left ventricular end diastolic volume indexed, LVESVi = Left ventricular end systolic volume indexed, LVEF = Left ventricular ejection fraction, LVMi = LV mass 
indexed, MAPSE = Mitral annular plane systolic excursion, RVEF = Right ventricular ejection fraction, SBP = systolic blood pressure, T1 = T1 relaxation time, T2 = T2 relaxation time, T2 SI ratio = T2 






Echo derived 2D LVEF was not significantly different across study visits. However, 
3D LVEF decreased significantly between baseline and completion of 
chemotherapy (61 ± 4 to 57 ± 4%, p = .001) and increased significantly between 
completion of chemotherapy and six month follow up (57 ± 4 to 60 ± 4%, p = 
.035). There was no significant difference between baseline and six month follow 
up (p = .81). Echo derived GLS did not differ significantly across study visits, 
though there was a trend towards worsened GLS from baseline to six month 
follow up  (-20.6 ± 2.6 to -18.9 ± 2.1%, p = .053). 
5.3.4 Electrocardiography 
One patient had ECG evidence of old anteroseptal myocardial infarction at 
baseline. No changes to rhythm, conduction intervals or ST segments, or T wave 
morphology were detected during the study. 
5.3.5 Troponin 
Troponin I increased significantly between baseline and completion of 
chemotherapy (4.3 ± 13.2 to 22.9 ± 29.9pg/ml, p = .02) but did not otherwise 
differ. Three patients (14%) exhibited subclinical cardiac injury (TnI of 0.06 to 
0.10ng/ml) on completion of chemotherapy. 
5.3.6 Cardiovascular physiology and symptoms 
The only significant change to physiological metrics during the course of the study 
was that diastolic blood pressure decreased significantly between baseline and 
six month follow up (78 ± 9 to 72 ± 13mmHg, p = .019; Table 5-2). At baseline, 
91% (22/24) of patients were NYHA class I. This had fallen to 66% (14/21) by 
completion of chemotherapy and 65% (11/17) by six month follow up. Seven 
patients (33%) and five patients (33%) reported NYHA class II dyspnea at 
completion of chemotherapy and six month follow up, respectively. One patient 







5.3.7 Recovery of left ventricular ejection fraction 
Patients were divided into tertiles according to CMR LVEF recovery between 
completion of chemotherapy and six month follow up (Figure 5-2). Baseline 
demographic and study data by tertile are displayed in Table 5-3. Patients in 
tertile 1 (poor recovery) trended towards being older than those in tertile 2 
(partial recovery) and tertile 3 (good recovery), though this difference was not 
significant (p = .11). Baseline CMR derived MAPSE was significantly different 
among tertiles of LVEF recovery, measuring 11.7 ± 1.5 mm, 13.7 ± 2.7 mm, 15.7 
± 3.1 mm in tertiles 1, 2 and 3, respectively (Figure 5-2; p = .028). Baseline 
myocardial T1 was also noted to be significantly different between tertiles, but 
measures were not ordinal, with tertile 2 exhibiting the highest values at baseline 
(Table 5-3). No data from completion of chemotherapy, nor change (∆) between 
baseline and completion of chemotherapy, were significantly different between 
tertiles of LVEF recovery, apart from LVEF at 6 month follow-up (Table 5-4). 
Echocardiography and CMR derived MAPSE correlated significantly (p < .001) but 
baseline echocardiography derived MAPSE was not significantly associated with 







Figure 5-2 Assessment of left ventricular function by tertile  
Panel A: Baseline CMR MAPSE by tertile of LVEF recovery. Panel B temporal absolute % change in LVEF by tertile. Visit 1 = baseline, visit 2 = 





Table 5-3 Baseline data by LVEF recovery tertiles 
 1 Poor 
recovery 
(n = 6) 
2 Partial 
recovery 
(n = 6) 
3 Good 
recovery 
 (n = 5) 
p value 
Mean age (years) 67 ± 6 51 ± 18 42 ± 24 0.11 
Female sex (%) 50 83 40 0.34 
BSA (kg/m2) 2.0 ± 0.3 1.9 ± 0.1 1.8 ± 0.1 0.59 
Dox (mg/m2) 296 ± 12 283 ± 58 274 ± 56 0.17 
CMR 
 LVEF (%) 
 MAPSE (mm) 
 2D FTGLS (%) 
 2D FTGCS (%) 
 2D FTGRS (%) 
 Myocardial T1 (ms) 
 Myocardial T2 (ms) 
Echo 
 3D LVEF (%) 
 GLS (%) 
 MAPSE (mm) 
 
60 ± 3 
11.7 ± 1.5 
-18.3 ± 3.1 
-22.2 ± 3.4 
49.6 ± 8.3 
1045 ± 30 
53 .0 ± 5.2 
 
60 ± 3 
-20.1 ± 2.5 
12.8 ± 2.1 
 
61 ± 4 
13.7 ± 2.7 
-21.7 ± 1.6 
-24.4 ± 2.6 
57.5 ± 12.7 
1077 ± 30 
54.6 ± 3.4 
 
64 ± 6 
-20.9 ± 2.5 
14.7 ± 2.5 
 
59 ± 4 
15.7 ± 3.1 
-21.7 ± 3.0 
-23.3 ± 4.0 
53.5 ± 11.3 
1022 ± 27 
52.9 ± 2.8 
 
58 ± 3 
-20.5 ± 3.0 













Values are mean ± standard deviation or n (%). 2D = two dimensional, 3D = three 
dimensional, CMR = cardiovascular magnetic resonance, Dox = Mean doxorubicin 
equivalent dose, FT = feature tracking, GLS = global longitudinal strain, GCS = 
global circumferential strain, GRS = global radial strain, LVEF = left ventricular 
ejection fraction, MAPSE = mitral annular plane systolic excursion, T1 = T1 






Table 5-4 Data from completion of chemotherapy and 6 month follow up by 
LVEF recovery tertile 
 1 Poor 
recovery 
(n = 6) 
2 Partial 
recovery 
(n = 6) 
3 Good 
recovery 
 (n = 5) 
p value 
Completion of chemotherapy 
CMR 
  LVEF (%) 
  MAPSE (mm) 
  2D FTGLS (%) 
  2D FTGCS (%) 
  2D FTGRS (%) 
  Myocardial T1 (ms) 
  Myocardial T2 (ms) 
Echo 
  3D LVEF (%) 
  GLS (%) 
 
54 ± 1 
12.0 ± 5.3 
-16.5 ± 2.7 
-21.4 ± 2.0 
44 ± 9  
1042 ± 3 
55.2 ± 2.8  
 
55 ± 4 
-18.4 ± 3.8 
 
53 ± 3  
12.3 ± 1.2 
 -18.8 ± 1.7  
-22.4 ± 1.6 
45 ± 6  
1082 ± 28 
59 ± 4 
 
60 ± 3 
-21.0 ± 4.2 
 
52 ± 4  
13.1 ± 1.0  
-18.4 ± 2.9  
-19.3 ± 5.9 
44 ± 13 
1045 ± 20  
56 ± 3 
 
55 ± 4  












6 month follow up 
CMR 
  LVEF (%) 
  MAPSE (mm) 
  2D FTGLS (%) 
  2D FTGCS (%) 
  2D FTGRS (%) 
  Myocardial T1 (ms) 
  Myocardial T2 (ms) 
 Echo 
  3D LVEF (%) 
  GLS (%) 
 
53 ± 1 
12.0 ± 2.6 
-17.5 ± 2.3  
-23.0 ± 1.1 
48 ± 5  
1072 ± 44 
53 ± 4  
 
56 ± 2 
-17.6 ± 1.5 
 
56 ± 2.5  
12.0 ± 2.2  
 -19.3 ± 2.2  
-22.6 ± 3.9  
52 ± 9  
1057 ± 36 
56 ± 4 
 
64 ± 2 
-20.3 ± 1.8 
 
57 ± 3  
13.8 ± 2.3  
-20.7 ± 2.5  
-21.9 ± 3.2 
51 ± 13 
1034 ± 10  
57 ± 3 
 
60 ± 3.3  












Values are mean ± standard deviation or n (%). 2D = two dimensional, 3D = three 
dimensional, CMR = cardiovascular magnetic resonance, Dox = Mean doxorubicin 
equivalent dose, FT = feature tracking, GLS = global longitudinal strain, GCS = 
global circumferential strain, GRS = global radial strain, LVEF = left ventricular 
ejection fraction, MAPSE = mitral annular plane systolic excursion, T1 = T1 
relaxation time, T2 = T2 relaxation time. 
In analysis of baseline MiRNAs according to tertiles of LVEF recovery, two 
MiRNAs were significantly dysregulated (likelihood ratio test) after false 
discovery rate correction: MiRNA-181-5p and MiRNA-221-3p (Figure 2-1). Both 
were expressed to a significantly higher degree in tertile 1, whose LVEF did not 





significant dysregulation of MiRNAs was detected on completion of 
chemotherapy according to patient groups defined by tertiles of LVEF recovery. 
 
Figure 5-3 Dysregulation of mMiRNAs at baseline by tertile of LVEF recovery 
The average log count per million is displayed along the X axis. Log fold change 
in dysregulation is displayed along the y axis. miRNA 181a-5p and miRNA-221-
3p display both elevated counts and upregulation among patients who exhibit 
poor recovery of LVEF. CPM = count per million, DE = Dysregulated expression. 
5.4 Discussion 
In this prospective, multiparametric CMR, echocardiography and blood 





reported. First, multiple measures of left ventricular systolic function (CMR LVEF; 
CMR FT GLS, GCS and GRS; echo 3D LVEF) deteriorate significantly on completion 
of anthracycline treatment compared with baseline. Second, several measures of 
systolic function recover over the next six months, with only CMR LVEF, CMR 
MAPSE, and CMR 2D FTGLS persistently depressed. Third, native myocardial T2 
mapping elevation occurred following anthracycline treatment but was not 
predictive of subsequent LVEF recovery. Fourth, no changes in native myocardial 
T1, ECV, LGE or LV mass were recorded with the caveat that only one patient met 
criteria for cardiotoxicity during the course of the study. Fifth, analysis of LVEF 
recovery by tertile revealed that CMR MAPSE was significantly different at 
baseline in patients exhibiting poor recovery of LVEF following completion of 
anthracycline. Furthermore, baseline expression of miRNA-181-5p and miRNA-
221-3p was significantly higher in those with poor LVEF recovery.  
5.4.1 CMR volumes and systolic function 
Commensurate with previous prospective studies of anthracycline 
cardiomyopathy82, 120, significant reductions in LVEF were observed early after 
completion of anthracycline treatment, which were driven by an increase in 
iLVESV (iLVEDV did not change). In addition, partial recovery of LVEF was 
observed late after anthracycline treatment and built on previous reports 
describing similar trends55, 179 by exploring baseline and early predictors of LVEF 
recovery by dividing the populations into tertiles of LVEF recovery. CMR derived 
MAPSE was the only baseline imaging metric significantly associated with LVEF 
recovery, which is a novel finding. Long axis systolic motion of the mitral annulus 
is an integral component of cardiac mechanics and the utility of CMR derived 
MAPSE as a powerful independent predictor of cardiovascular outcomes has 
recently been reported in the context of hypertension198 and myocardial 
infarction199.  Indeed, it is reported that long axis motion (for which MAPSE is a 
surrogate) is responsible for approximately 60% of stroke volume200. 
Furthermore, MAPSE can be calculated quickly and easily from standard cine 





derived MAPSE as a baseline predictor of LVEF recovery after anthracycline 
treatment may potentially be of clinical interest in selecting patients for more 
frequent monitoring or the institution of preventive therapies, though 
confirmation by larger, powered prospective studies is certainly required. It is 
also noteworthy that despite the administration of comparatively high doses of 
anthracycline to a patient cohort with coexisting haematological malignancy and 
increasing breathlessness (judged by NYHA class), only one patient met the 
criteria for cardiotoxicity during the course of the study, highlighting the fact that 
in the vast majority of patients, changes were subclinical. 
5.4.2 CMR strain 
The study prospectively documented anthracycline related changes in 2D FT 
strain in all three planes and as such, provides novel insight. All measures of CMR 
strain were significantly impaired on completion of anthracycline treatment. 
However, FTGCS and FTGRS were statistically comparable to baseline by the end 
of the study, whereas FTGLS remained persistently impaired. These data support 
and replicate previous work by Ong et al.84 who reported similar finding for FTGLS 
and FTGCS in a prospectively studied cohort of breast cancer patients treated 
with trastuzumab, half of whom also received anthracycline. However, measures 
of strain at baseline and on completion of chemotherapy were not associated 
with subsequent LVEF recovery. 
5.4.3 CMR T1 and T2 mapping  
Recent animal data demonstrated that T2 mapping abnormalities are the earliest 
marker of cardiotoxicity, which manifested histopathologically as 
intracardiomyocyte vacuolisation5. Importantly, cessation of anthracycline at this 
stage (6 weeks after initiation of 0.45mg/kg intracoronary doxorubicin, 
administered on alternate weeks) led to resolution of imaging and histological 
changes, whereas continuation led to progressive abnormalities of imaging, 
histological and functional markers, thus potentially identifying cardiotoxicity at 
a reversible stage5. In turn, human studies have reported significant 91, 201 and 





chemotherapy, though their relationship to subsequent cardiac dysfunction is 
hampered by short duration of follow up120, 201 and lack of sequential data 
collection91. This study provides additional evidence of significant elevation of T2 
mapping early after chemotherapy, with prospective evaluation confirming 
resolution of T2 mapping over a longer follow up period. However, early T2 
mapping elevation was not associated with subsequent LVEF recovery, either on 
a grouped or individual level and therefore the translational clinical utility of this 
finding in human studies is yet to be confirmed. 
The potential role of native T1 mapping and ECV in the detection of early 
cardiotoxicity have been highlighted by animal67 and human55, 91, 120, 201 studies 
describing significant temporal changes. By contrast, no significant changes to T1 
mapping or ECV were found during the course of the study. This discrepancy may 
partly relate to the differing imaging timing and populations studied (this is the 
only study exclusively of haematological malignancies), the low incidence of 
cardiotoxicity, as well as the confounding effects of potent anti-inflammatory 
treatment (58% received concomitant steroid in the study; not reported by 
others) and cancer itself108 on native T1 mapping and ECV. In addition, the 
technical evolution of the MOLLI sequence employed may have conferred 
reduced sensitivity to detect myocardial inflammation, compared to previous 
iterations. When taken in combination with a recent report of overlapping 
temporal variability between patients and healthy controls186, the precise 
translational role for these sequences in modern monitoring strategies is yet to 
be defined. 
5.4.4 Echocardiography 
Echocardiography is the most accessible and widespread method to monitor 
cardiac function during anthracycline therapy2. Despite changes in multiple CMR 
metrics, only 3D LVEF changed significantly, in keeping with a previous report 
highlighting the relative lack of sensitivity of 2D methods to detect temporal 





predictors of LVEF recovery were identified. It is also noteworthy that while echo-
derived GLS trended towards initial impairment and subsequent recovery, these 
changes did not meet statistical significance. This may be accounted for by the 
small sample size and recognised intra-observer variability of this technique.  
5.4.5 MicroRNAs 
Circulating miRNAs regulate target gene expression and are an appealing 
biomarker because they are readily quantifiable, have a long half life, and remain 
stable at extremes of temperature and pH. However, few human studies have 
examined their utility to detect anthracycline cardiotoxicity, and have reported a 
range of expression profiles68, 70, 202. In this study analysing predictors of LVEF 
recovery after completion of anthracycline, it was identified that miRNA-181a-5p 
and miRNA-221-3p were significantly increased at baseline in patients whose 
LVEF showed poor recovery after anthracycline chemotherapy. A recent 
systematic review and meta-analysis reported that miRNA-221 was associated 
with a poor overall survival in human carcinoma203 and miRNA 181a-5p 
expression has been associated with poor outcomes in patients with colorectal 
cancer204 but their role in anthracycline cardiotoxicity has not been reported 
previously. Therefore, it is uncertain whether increased miRNA levels at baseline 
signify susceptibility to cardiotoxicity or are a broader marker of more advanced 
or aggressive malignancy with an adverse prognosis. Indeed subclinical functional 
and morphological cardiac dysfunction has previously been linked to cancer 
itself205 independent of chemotherapy and further scientific exploration of these 
relationships is warranted. 
5.4.6 Study limitations 
This study intentionally recruited a homogenous cohort of patients to minimise 
baseline confounding factors and used specific hardware and software to collect 
and analyse data, which reduces the external validity of the results to other 
populations and clinical systems. This was a pilot study, powered to detect 
temporal changes in LVEF and as such, secondary analysis for baseline and early 





validation before firm conclusions can be drawn. The low incidence of 
cardiotoxicity and absence of major adverse cardiovascular events over a 
relatively short follow up period mean that the impact of the observed subclinical 
temporal changes on clinical outcomes has not been established. 
5.4.7 Conclusions 
In this prospective multimodality pilot study of anthracycline cardiotoxicity, 
several significant temporal changes to cardiac systolic function and tissue 
characteristics in response to anthracycline treatment have been demonstrated. 
Importantly, a degree of recovery of LVEF between completion of chemotherapy 
and six month follow up is confirmed in the majority of patients. Baseline CMR 
derived MAPSE and baseline circulating miRNA-181-5p, and -221-3p were 
associated with poor recovery of LVEF six months after completion of 
anthracycline chemotherapy. Pending validation by larger studies, these 
potential ‘predictive’ biomarkers may be a useful tool to inform individualised 
treatment and monitoring strategies for patients scheduled to receive 
anthracycline treatment. 
5.5 Novel findings 
1. Baseline CMR derived MAPSE and baseline circulating levels of miRNA-
181-5p and miRNA-221-3p were associated with poor recovery of LVEF six 






Chapter 6 General Discussion 
It is not practical, possible, nor indeed desirable to undertake CMR in all patients 
receiving potentially cardiotoxic treatment and therefore, its use in this setting 
must be adjudicated carefully, balancing resource use, clinical need and the latest 
scientific evidence. In this thesis, important insights that are uniquely provided 
by multiparametric CMR and may potentially be of interest at several stages of 
the cancer patient pathway have been described. Below is a summary of the main 
contributions to the field of CMR in cardio-oncology. 
6.1 Summary of major findings 
1. Confirmation that late stage anthracycline cardiomyopathy is 
characterised phenotypically by pathological increase in LVESVi. 
2. Confirmation that focal fibrosis (adjudicated by the presence of LGE) is 
not a common finding (19%) in late stage anthracycline cardiomyopathy  
3. Novel finding that the presence of focal fibrosis is associated with 
adverse left ventricular remodelling and reduced LVEF. 
4. Novel findings that elevated native myocardial T1 mapping values 
(surrogate CMR marker of diffuse fibrosis) are more common (36%) in late 
stage anthracycline cardiomyopathy and are associated with adverse left 
ventricular remodelling, reduced LVEF and hospitalisation for heart 
failure. 
5. Novel finding that anthracycline treated cancer survivors with a normal 
LVEF have significant perturbations of GLS (2D and 3D), native myocardial 
T1, ECV, indexed LV mass and indexed myocardial cell volume, compared 





6. Novel finding that indexed myocardial cell volume, which serves as a 
surrogate marker of cardiomyocyte loss, is inversely associated with 
anthracycline dose, using modern dose capped regimens. 
7. Confirmation that CMR 2D and 3D feature tracking strain, native T1 and 
ECV display good to excellent levels of inter- and intra-observer 
reproducibility. 
8. Confirmation that prospective non-invasive evaluation of patients 
receiving anthracycline treatment with CMR echocardiography and blood 
biomarkers identifies multiple, significant temporal changes in cardiac 
structure and function from treatment initiation to 6 months after 
completion of treatment. 
9. Novel finding that baseline CMR derived MAPSE and baseline circulating 
levels of miRNA-181-5p and miRNA-221-3p were associated with poor 






6.2  Translational outlook 
In chapter 2, the scientific evidence was critically reviewed, CMR imaging 
sequences discussed, guideline based clinical indications presented and 
indication specific CMR protocols proposed. This chapter serves as a useful 
summary of the current role of CMR in evaluating patients receiving potentially 
cardiotoxic therapy. The findings contribute to this body of evidence and provide 
further insight into potential applications of CMR in the evaluation and 
monitoring of patients receiving cancer therapy. Specific features of 
anthracycline cardiomyopathy not identifiable by other methods have been 
demonstrated, and potential baseline markers of susceptibility to anthracycline 
cardiomyopathy, which are of potentially significant interest to inform risk 
stratification and monitoring strategies have been demonstrated. However, 
further validation studies are required and the integration of these findings and 
indeed CMR in general, into clinical monitoring strategies has several barriers to 
overcome. Despite encouraging data on the utility of tissue characterisation 
sequences to identify cardiotoxicity early in animal models5, in line with other 
human studies91, a role for these sequences in current clinical practice was not 
identified. This may partly be explained by the heterogeneity of adult human 
subjects compared with animal models but concerns regarding the temporal 
variability and overlap of these parameters with healthy control subjects186 are 
legitimate and merit further exploration. Recent work specifically addressing  the 
variability in echocardiographic and CMR assessment of left ventricular function 
identified 3D echo-LVEF, 2D echo GLS and CMR-LVEF as the most reproducible 
parameters exhibiting the least overlap with variability in healthy volunteers206, 
indeed CMR LVEF had the lowest variability in this study. Therefore, following a 
baseline CMR study, a shortened protocol where only cine imaging is acquired to 
permit LVEF assessment could be employed for serial evaluation and could be 
accomplished efficiently (10-15 minutes) and without the need for contrast. The 
advent of compressed sensing and rapid acquisition protocols could streamline 






This thesis provides several important insights into the cardiovascular effects of 
cancer therapy. However, the data presented have several important limitations. 
The data presented in chapters 3 and 4 were collected retrospectively, and as 
such, are subject to referral bias. All the data were collected at a single centre 
using specific hardware and software, which impacts its external validity. 
Furthermore, the data consist of small sample sizes. Small sample sizes are 
subject to both type I and type II errors and as such, require further validation by 
larger studies. That being said, the sample sizes compare favourably with other 
CMR studies in the field (Table 2-2) and as a body of work, provide important 
insights into several aspects of anthracycline cardiomyopathy.  This also 
illustrates the difficulty of researching clinical conditions with low incidence and 
prevalence, where small sample sizes may be all that are available. In chapters 4 
and 5, the design, methodology and results of a prospective study that was 
powered to detect a change in LVEF and based on the anticipated incidence of 
newly diagnosed haematological malignancy during the study period in the local 
clinical catchment are reported. Exploratory analysis identified three previously 
unreported baseline predictors of recovery of LVEF at six months. However, it is 
important to note that the study was not adequately powered to detect baseline 
predictors, which in terms of informing treatment and monitoring strategies, 
would be one of the most clinically useful findings. Pragmatically, the sample size 
was constrained by the incidence of disease, funding, and time constraints, all of 
which are difficult to overcome. Therefore, further study is required to validate 






Chapter 7 Future directions 
There are a multitude of unanswered questions regarding the role of CMR in the 
field of cardio-oncology and the progressive incorporation of this unique tool into 
clinical guidelines and subsequently, clinical practice, requires a sound evidence 
base.  Building on the work presented in this thesis, further evaluation and 
validation of non-invasive predictors of cardiotoxicity at baseline is warranted. 
Baseline predictors of cardiotoxicity may represent the most clinically useful 
piece of information, allowing clinicians to design individualised risk stratification, 
monitoring, treatment and preventive strategies for their patients.  As discussed 
in section 6.2, an assessment of CMR in comparison to echocardiography (current 
practice), ideally in the form of an RCT should be conducted in patients receiving 
cardiotoxic therapy to determine if one method is superior. If these assessments 
could be of comparable cost and resource use, which may be achievable with 
shortened, contrast free CMR protocols, this would be of additional value.   
In addition, exercise intolerance is a feature of cancer therapy and indeed, cancer 
itself207. The majority of CMR studies to date have evaluated cardiac function at 
rest, with only a few exceptions167. However, studying cardiac function during 
exercise CMR may provide important insights, which may be of more clinical 
relevance to the patient’s symptoms and quality of life, the latter of which has 
also only been evaluated by a small number of studies82. Finally and perhaps most 
importantly, data regarding the prognostic implications of non-invasive 
biomarker derangement to hard clinical endpoints in cardio-oncology 
populations are lacking and large scale, multicentre studies are required to obtain 
sufficient statistical power to address this area of clinical uncertainty. In addition, 
the role and clinical impact of training and employing dedicated cardio-oncology 
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Chapter 9  Appendix - Prospective Study Protocol 
9.1 Introduction 
Cancer is a leading cause of illness and death but mortality rates are falling 
predominantly because of improvements in chemotherapy, radiotherapy and 
supportive care. However, a wide range of cancer therapies have been associated 
with cardiotoxicity, leading to significant cardiovascular morbidity and 
sometimes causing death. Anthracyclines, commonly used to treat 
haematological malignancy, are the most frequently implicated agents19.  
Agents used in the treatment of cancer have unique cardiotoxic effects that vary 
in the extent, pattern and timing of cardiac injury.  This injury can be fully 
reversible, partially reversible or irreversible. Individual susceptibility varies and 
the full effects may not become apparent for months or years later, as evidenced 
by survivors of childhood cancer. Consequently, the non-invasive 
echocardiographic evaluation of left ventricular function, commonly by 
measuring either LVEF or GLS in patients receiving potentially cardiotoxic 
treatment has become established practice.  If a significant deterioration in LVEF 
occurs, chemotherapy is modified or withdrawn and cardioprotective treatment 
initiated. However, the expression of cardiac damage by deteriorating left 
ventricular systolic or diastolic function may not be detectable by 
echocardiography until a significant amount of cardiac injury has occurred101.  
CMR has emerged as the reference standard for measuring left ventricular 
volumes, mass and ejection fraction with a greater ability to identify subtle 
changes to cardiac structure and function than echocardiography77. In addition, 
cardiac MRI has the unique capability to characterise myocardial tissue non-
invasively, providing a virtual biopsy of histopathological changes and early 





provides an opportunity to modify or withdraw cancer therapy, implement 
primary prevention strategies and potentially avoid irreversible cardiac injury. 
To date, there are only a limited number of small, mainly retrospective studies 
using cardiac MRI to evaluate cardiotoxicity due to cancer therapies (Table 2-2) 
and only one study of ten participants specifically evaluating patients treated for 
haematological malignancy102. However, these initial reports suggest an evolving 
role for cardiac MRI in evaluating early and late chemotherapy related cardiac 
injury. 
Furthermore, there is increasing interest in the role of non-coding RNAs (ncRNA) 
e.g. microRNA, long non-coding RNA and circular RNA, as potential biomarkers of 
cardiovascular disease with reports of identifiable deregulation both in rats208 
and in human induced pluripotent stem cell derived cardiomyocytetes209 exposed 
to anthracycline with emerging reports of dysregulation in human studies68. 
The diagnostic and prognostic role of cardiac MRI and novel biomarkers in 
patients treated with potentially cardiotoxic therapy for haematological 
malignancies, including those undergoing haematopoietic cell transplantation 
merits further evaluation.  
9.2 Background 
9.2.1 Anthracycline cardiomyopathy 
Improvements in cancer therapy and supportive care have led to significant 
improvements in cancer survival. However, survivors are at increased risk of 
cardiovascular disease, partly because cancer and cardiovascular disease share 
common risk factors (smoking, age, and obesity) but also because chemotherapy 
itself can cause cardiac injury. Anthracyclines and related compounds that are 
often used to treat haematological malignancy are the most frequently 
implicated agents, leading to significant cardiovascular morbidity and sometimes 





formation, transcriptional changes in intracellular triphosphate production in 
cardiac myocytes and through interaction with cardiac topoisomerase IIβ3. At the 
tissue level, this manifests as myocardial inflammation210, oedema4 and 
vacuolisation43, which seem to predate overt impairment of left ventricular 
function. During the later stages of anthracycline cardiomyopathy, myocardial 
fibrosis as evidenced by LGE has been described117, though these findings have 
not been widely reproduced. In the context of overt heart failure, mortality can 
be as high as 60% at two years7, emphasising the importance of early 
identification of cardiac injury, the modification of therapy, the institution of 
primary prevention strategies and avoidance of long term cardiovascular 
complications. No established definition of early cardiovascular injury in this 
setting exists but a > 5% drop in LVEF in association with symptoms or a > 10% 
asymptomatic drop in LVEF to a value below the lower limit of normal is 
commonly used2. Therefore, cardiovascular imaging has an important role in 
detecting early cardiac injury. 
9.2.2 Current use of cardiovascular imaging to detect anthracycline 
cardiomyopathy 
9.2.2.1 Echocardiography 
In the United Kingdom, 2D transthoracic echocardiography is commonly used to 
screen and monitor patients receiving potentially cardiotoxic cancer therapy.  
However, it is relatively insensitive to small reductions in EF211, though sensitivity 
may be improved by using 3D echo or intravenous contrast. Myocardial strain 
imaging, particularly GLS, may be better able to identify subtle changes to left 
ventricular function with an early reduction in strain predictive of subsequent 
cardiomyopathy117. However, the challenges of an adequate acoustic window 
remain. 
9.2.2.2 CMR  
CMR is considered the gold standard for measurement of left ventricular volumes 





non-invasively, thus providing a virtual biopsy of histopathological changes and 
an opportunity to identify subclinical cardiac injury prior to deterioration in left 
ventricular function. Additional strengths include the lack of ionizing radiation 
and lack of dependence on assumed geometric models or on an adequate 
acoustic window. However, the lack of widespread availability and higher 
operational cost mean that it is currently recommended only when the 
discontinuation of cancer therapy is being considered or when echocardiographic 
data are thought to be unreliable or conflicting19.   
Contrast enhanced cardiac MRI is a well established non-invasive imaging tool. 
Gadolinium is an extracellular agent that accumulates in areas of interstitial 
expansion and permits the quantification of focal myocardial fibrosis and 
infiltration by assessing LGE212. The most common finding in anthracycline 
induced cardiomyopathy is absence of LGE but lateral wall LGE has been reported 
in one single centre study117. Other specialised sequences allow characterisation 
of pathological tissue without contrast. A T2 weighted sequence, Short-Tau 
Inversion Recovery (STIR), identifies increases in tissue free water content e.g.  
due to myocyte swelling and interstitial oedema. To date, only one small 
published paediatric study90 has reported acute myocardial oedema in patients 
receiving anthracyclines.  Furthermore, the introduction of T1 and T2 mapping, a 
quantitative tool to identify diffuse myocardial processes not detectable by 
traditional LGE imaging has added a new dimension to the understanding and 
assessment of various myocardial diseases. T1 mapping promises to detect early 
disease, objectively quantify disease severity, and may provide prognostic 
insights into certain conditions. Using this technique, an increased ECV, used as a 
surrogate marker of myocardial fibrosis, was reported in a cohort of patients 
receiving anthracyclines, compared with age and sex matched controls107. 
However, the routine use of CMR in clinical practice is limited by its availability 







Considerable investigative effort has been devoted to the role of biomarkers as 
early markers of cardiac injury. Cardiac troponins are the gold standard 
biomarker for identifying myocardial injury and have been reported to predict LV 
dysfunction in patients receiving cardiotoxic chemotherapy52. However, the 
optimal timing of sampling is unclear, the optimal cut off level for determining 
positivity has not yet been established2 and those with positive Troponin assays 
may go on to develop irreversible LV dysfunction. Therefore, their use in this 
context is yet to enter routine clinical practice.  
More recently, non-coding RNAs (including microRNA, long non-coding RNA, and 
circular RNA) have showed promise in the cardiovascular arena for their potential 
as novel biomarkers as well as therapeutic targets. For instance, different 
microRNAs have been implicated in the pathogenesis of a variety of 
cardiovascular diseases66 and have consequently become an appealing diagnostic 
and therapeutic target. This applies both to microRNA circulating in the blood, 
but also, interestingly, to those carried by extracellular vesicles known as 
exosomes.  A recent study reported that the plasma concentration of exosomes 
carrying a cargo of cardiac microRNAs is increased following coronary artery 
bypass graft surgery213. The role of microRNAs as early biomarkers of 
anthracycline induced cardiac injury has been explored in animal models214 and 
latterly in human induced pluripotent stem cell derived cardiomyocytes209. 
Interestingly, several microRNAs showed either early or prolonged deregulation 
in response to anthracycline, the former prior to the emergence of markers of 
cytotoxicity. However, these findings are yet to be explored in human subjects. 
9.2.3 Rationale for the study 
Whilst survival of cancer patients is improving, the unintended cardiovascular 
side effects of cancer treatment carry significant implications for cancer 
survivors. Subclinical, cancer therapy induced cardiac injury can be difficult to 
predict and/or detect with transthoracic echocardiography because it is relatively 





to either predict or identify cardiac injury at an earlier stage, thus limiting the 
extent of injury and potentially avoiding serious late clinical sequelae.  Cardiac 
biomarkers, particularly miRNAs, also show promise in being able to predict 
cardiotoxicity or identify it during the early, reversible phase.  If cardiotoxicity can 
be identified or predicted, the opportunity to tailor monitoring strategies, adjust 
therapy, institute primary prevention strategies and ultimately, avoid significant 
cardiovascular sequelae may be afforded, thus maximising benefit, minimising 
risk and improving patient outcomes. Few studies have employed CMR to study 
anthracycline cardiotoxocity prospectively and none have previously combined 
this evaluation with simultaneous miRNA analysis.   
9.3 Study aims 
9.3.1 Primary aim 
To prospectively characterise anthracycline cardiotoxicity in patients receiving 
cancer therapy for haematological malignancy using multiparamtetric CMR and 
novel biomarkers. 
9.3.2 Secondary aims 
To explore baseline and early non-invasive parameters that predict subsequent 
development of, and recovery from anthracycline cardiotoxicity in patients 
receiving cancer therapy for haematological malignancy. 
9.4 Experimental Hypothesis 
9.4.1 Hypothesis for primary aim 
The null hypothesis states that there will be no significant changes to measured 
parameters during the course of the study. The alternative hypothesis states that 
there will be significant temporal changes to study parameters during the course 






9.4.2 Hypothesis for secondary aim 
The null hypothesis states that there will be no baseline or early non-invasive 
parameters that predict the development of or recovery from anthracycline 
cardiotoxicity. The alternative hypothesis states that there will be baseline or 
early non-invasive parameters that predict the development of or recovery from 
anthracycline cardiotoxicity 
9.5 Outcome measures 
9.5.1 Primary outcomes 
Prospective change in LVEF assessed by CMR 
9.5.2 Secondary outcomes 
Prospective change in T1, T2 mapping and Extracellular Volume (ECV) values, 
assessed by CMR 
Prospective change in 2D global longitudinal, circumferential, and radial feature 
tracking CMR derived strain. 
Prospective change in 2D and 3D LVEF and 2D GLS by echocardiography  
Prospective change in biomarkers of cardiac injury (Troponin and miRNA) 
9.5.3 Additional outcomes 
Baseline and early predictors of LVEF recovery between completion of 
chemotherapy and six month follow up will be explored. 
9.6 Study design  
This was a multicentre cohort study to investigate the role of CMR and novel 
biomarkers (miRNAs, Troponin I) to identify cardiac injury in patients receiving 
potentially cardiotoxic treatment for haematological malignancy. The study 





cardiotoxic treatment for haematological malignancy, including those 
undergoing haematopoietic stem cell transplantation. 
The study was conducted at two centres; The Bristol Haematology and Oncology 
Centre, which is part of the Bristol Royal Infirmary, University Hospitals Bristol 
NHS Trust, and Southmead Hospital, North Bristol NHS Trust. Southmead Hospital 
was a Participant Identification Centre (PIC). The Bristol Royal Infirmary (including 
The Bristol Haematology and Oncology centre and The Bristol Heart Institute) was 
the main research centre, conducting all research activities. 
9.6.1 Subjects and recruitment 
Participants were identified from those attending the haematology clinic at the 
Bristol Haematology and Oncology Centre and Southmead Hospital by reviewing 
their medical records. Participants were initially be approached and provided 
with verbal and written information by a member of the direct care team, usually 
a consultant haematologist or haematology specialist registrar. All staff involved 
in identifying potential participants had substantive or honorary contracts with 
the relevant trust and were members of the direct care team. If an interest in 
taking part was expressed, further questions were answered either by a member 
of the direct care team or by a clinical research fellow. Consent was obtained by 
a member of the direct care team or a clinical research fellow. 
9.6.1.1 Inclusion criteria 
Participant may enter study if ALL of the following apply 
1.  Age ≥ 18 years 
2. Newly diagnosed haematological malignancy  
(Either high grade non-Hodgkin lymphoma scheduled for ≥ 6 cycles 
anthracycline, Hodgkin Lymphoma scheduled for ≥ 6 cycles 
anthracycline or Acute Myeloid Leukaemia scheduled and fit for 





9.6.1.2 Exclusion criteria 
Participant may not enter study if ANY of the following apply 
1. Contraindications to CMR (Ferromagnetic foreign body, severe 
claustrophobia, severe renal impairment) 
2. Contraindications to Gadolinium contrast (severe renal failure 
[eGFR < 30], previous allergy, pregnancy, or breastfeeding)  
3.  Unable to give consent 
4.  Prisoners 
5. Prior cardiac disease (e.g. impaired LVEF, myocardial infarction, 
percutaneous coronary intervention, coronary artery bypass 
grafting or other cardiac surgery or invasive procedure, ≥ 
moderate valvular heart disease, congenital heart disease, 
arrhythmia, hypertrophic cardiomyopathy, amyloidosis, 
sarcoidosis or intracardiac mass) 
6.  Prior haematological disease or malignancy 






9.6.2 Study schedule   
 
 






9.6.3 Participant pathway 
 
Figure 9-2 Participant pathway 
9.7 Study Procedures 
9.7.1 Baseline data 
Baseline data were collected by the research team and recorded in a case report 
form (CRF). Data included date of birth, ethnicity, sex, medical history, prescribed 
medications and smoking and alcohol status. 
9.7.2 Symptom enquiry 
A cardiovascular focused symptom enquiry was undertaken at each study visit 
including New York Heart Association (NYHA) dyspnoea class and the presence of 
orthopnoea or paroxysmal nocturnal dyspnoea.  
9.7.3 Physiological data 
Weight and height were measured at the beginning of each study visit and 
recorded in the CRF. Body surface area (Mosteller) was calculated and body mass 





standard 12 lead surface electrocardiogram was recorded in a semi supine 
position, interpreted by the research team and the result (including heart rate in 
beats per minute) recorded in the CRF. Blood pressure was recorded with the 
participant lying supine in the MRI scanner using an appropriately sized 
automated blood pressure cuff and the result recorded in the CRF.   
9.7.4 Blood sampling 
Venepuncture was performed according to standard procedures using aseptic 
technique.  Near patient analysis of blood samples was undertaken using an iSTAT 
(Abbott laboratories, United States of America) testing unit. Readings were 
printed from the analyser and recorded in the CRF. The iSTAT testing unit was 
calibrated and control samples analysed with each new box of testing cartridges 
in accordance with the manufacturer’s instructions. 
9.7.5 MicroRNA 
Following venepuncture, 5 ml of blood was drawn into a sodium citrate 
vacutainer. This was transported to the laboratory and centrifuged at 2240 g for 
10 minutes at room temperature. The plasma supernatant was removed to a 
fresh Eppendorf tube without disturbing the buffy coat and centrifuged again at 
2240 g for 10 minutes at room temperature. The supernatant was then removed 
to a fresh Eppendorf LoBind microcentrifuge tube, pseudo-anonymised and 
stored at -80°C in preparation for blinded batch analysis. See Appendix Error! 
Reference source not found. for detailed miRNA processing protocol. 
9.7.6 CMR 
CMR was performed at each study visit following confirmation of consent. The 
CMR study protocol is included in Appendix Error! Reference source not found. 
and specific technical information is described in section 5.2.1.  
9.7.7 Echocardiography 
Echocardiography was performed on the same day as CMR and blood biomarker 
analysis. All analyses were performed on a single EpiQ machine (Philips, 





study protocol is included in Appendix Error! Reference source not found. and 
specific technical information is described in section 5.2.2. 
9.8 Statistics 
9.8.1 Justification of target sample size 
Based on a combination of prior publications of change in LVEF, a target sample 
size of 14 subjects gives 90% power at an alpha level of 0.016 to detect a 
statistically significant difference of 6.2% in LVEF (61.5 ± 2.9% vs. 55.3 ± 3.1%). 
There are few, if any, previously published data on myocardial oedema, T1 and 
T2 mapping or microRNA in this setting in human subjects to guide power 
calculations and, as such, this aspect is considered exploratory. Overall, the aim 
was to recruit 25 subjects over a period of one year, based on the incidence of 
disease and an anticipated recruitment rate of 25%. 
9.9 Safety reporting 
This study did not require participants to undergo additional therapeutic 
interventions.  Therefore, it was felt unlikely that clinical adverse events (AE) 
could be attributed to study specific procedures. AE’s arising from procedures 
that constitute standard care were not reported. Expected events due to study 







Table 9-1 Expected adverse events not to be reported 
Procedure Expected outcomes 
Insertion of intravenous cannula Pain, bleeding, bruising, fainting, 
local skin irritation or inflammation, 
localised skin reaction to dressing 
Electrocardiogram Local skin irritation to adhesive pads 
Echocardiogram Local skin irritation to adhesive pads 
CMR Nausea, headache, claustrophobia, 
anxiety. 
 
Any other AE arising during the conduct of the study was reported in accordance 
with the process for reporting adverse events set out by University Hospitals 
Bristol and The University of Bristol. 
The University has a Service Level Agreement with UH Bristol to ensure that all 
SAE reporting is managed by UH Bristol on behalf of the University. For that 
reason, all SAEs must be recorded and reported to UH Bristol, in accordance with 
UH Bristol Research Safety Reporting Standard Operating Procedure. UH Bristol 
will regularly inform the University about SAEs. Expedited reporting takes place 
where necessary to agree corrective / preventative actions. 
9.10 Ethical considerations 
9.10.1 Risks and anticipated benefits 
This was an observational study that did not change the patients’ standard care.  
There were therefore few anticipated risks to patient safety resulting from the 





above; Table 9-1. Clinical reports were not issued for research scans unless there 
was an explicit request from the clinical team to help inform clinical care. 
However, if a significant, unexpected abnormality e.g. previously unrecognised 
myocardial infarction was discovered, the finding was communicated on an 
urgent basis to the clinical team in the best interests of the patient. 
The main benefit of the study was the provision of high quality evidence to 
address this important area of clinical uncertainty. 
9.10.2 Informing potential participants of possible benefits and known 
risks 
Information about possible benefits and risks of participation were described in 
the patient information sheet (PIS).  Participants were provided with the 
opportunity to ask questions and as much time as they required regarding the 
benefits and risks of participation prior to enrolment.  
9.10.3 Obtaining informed consent 
Written, informed consent was obtained from each participant prior to entry into 
the study. This was obtained either by a trained member of the direct care team 
or by a trained clinical research fellow in a confidential environment (outpatient 
clinic of either the Bristol Haematology and Oncology Centre or Southmead 
Hospital). Eligible participants were provided with written information, allowed 
to ask questions and as much time as they required to decide whether they 
wanted to take part. The research fellow or member of the direct care team or PI 
were responsible for the consent process. 
9.11 Research governance 
This study was conducted in accordance with: 
• International Conference for Harmonisation of Good Clinical Practice (ICH 
GCP) guidelines 





9.11.1 Sponsor approval 
Any amendments to the study documents were approved by the sponsor prior to 
submission to the HRA. 
9.11.2 Study permissions 
The study was performed subject to NHS Research Ethics Committee (REC) and 
Health Research Authority (HRA) approval, including confirmation of capacity and 
capability from participating NHS organisations. 
Any amendments to the study, after a favourable opinion from the HRA and NHS 
REC had been given were submitted to the Sponsor for review prior to submission 
for regulatory approval and implementation. 
9.11.3 Investigators’ responsibilities 
Investigators were required to ensure that all required local research permissions 
had been obtained and that any contractual agreements required were signed 
off by all parties before recruiting any participant.  Investigators were required to 
ensure compliance with the protocol and study manual.  Investigators were 
required to allow access to study documentation or source data on request for 
monitoring visits and audits performed by the Sponsor or any regulatory 
authorities. 
Investigators were required to read, acknowledge, and inform their study team 
of any amendments to the study documents approved by the HRA that they 
receive and ensure that the changes were complied with. 
9.11.4 Monitoring by sponsor 
The University of Bristol (UoB) has a Service Level Agreement in place with a local 
NHS Trust (UH Bristol). As part of this, UH Bristol undertake monitoring of 
research projects where UoB is fulfilling the responsibilities of a research sponsor. 






The University of Bristol has arranged Public Liability insurance to cover the legal 
liability of the University as Research Sponsor in the eventuality of harm to a 
research participant arising from management of the research by the University. 
This does not in any way affect an NHS Trust’s responsibility for any clinical 
negligence on the part of its staff (including the Trust’s responsibility for 
University of Bristol employees acting in connection with their NHS honorary 
appointments). 
The NHS indemnity scheme applied for insurance and/or indemnity to meet the 
potential legal liability of the sponsor or employer for harm to participants arising 
from the design of the research. 
All medical and academic staff conducting the research held honorary contracts 
with Bristol University Hospitals NHS Foundation Trust giving them the protection 
of the NHS indemnity scheme. 
9.12 Data protection  
Data were collected and retained in accordance with the UK Data Protection Act 
1998. 
9.12.1 Data handling, storage and sharing 
9.12.1.1 Data handling 
Study data were uploaded to the NHS PACS server hosted at the UH Bristol NHS 
Trust. Data transmitted from the NHS server to the University of Bristol were 
pseudo-anonymised by assigning a unique participant identifier and removing all 
patient identifiable information other than the unique identifier.  The “look up” 
table for the unique participant identifier remained on the NHS server. Standard 
operating procedures for database use, data validation and data cleaning were 
available and regularly maintained.   





All the imaging data were stored in the UHB PACS system. The site files, including 
participant consent forms were kept securely in the NHS CMR Unit of the Bristol 
Heart Institute. The study data were stored and maintained in a pseudo-
anonymised form in a Bristol University RedCap database. 
